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I. INTRODUCTION 
Cystic Fibrosis (CF) is one of the most common life-threatening hereditary 
diseases in people of European descent. Mutations in the gene coding for the 
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) lead to defective 
anion transport on epithelial surfaces and thereby cause a multisystemic disease 
mainly affecting the airways and the pancreas (Davies, Alton et al. 2007). From 
childhood on, patients have to undergo a multitude of symptomatic treatments for 
the management of pulmonary and gastrointestinal disease (Cystic Fibrosis 
Foundation 2016). Efforts in intensive symptomatic therapy have revolutionized 
the treatment of CF patients, leading to an increase of the median survival age 
from early childhood for a child diagnosed with CF in the 1950s to about 37 years 
for a CF patient today (Dodge, Lewis et al. 2007, MacKenzie, Gifford et al. 
2014). However, treatment options are still mainly limited to symptomatic 
therapy. 
For a better understanding of pathophysiological mechanisms involved in the 
onset of the disease and evaluation of novel therapeutic approaches aiming at the 
underlying cause of CF, animal models are an essential tool. Efforts in genome 
manipulation during the past decade have facilitated the establishment of different 
animal models for human genetic disorders. From the five CF animal models 
developed so far (mouse, rat, ferret, pig and zebrafish), the porcine CF model 
proves to be the model showing the closest resemblance to the typical CF 
phenotype in humans (Cutting 2015). Until now, a range of important insights, 
mainly regarding the inflammatory and infectious processes involved in the 
development of pulmonary disease, have been gained by studies on porcine CF 
tissue. However, the utility of the porcine CF model is still hampered, as CF 
piglets cannot reach adulthood due to a severe meconium ileus that occurs in 
100 % of all cases. This neonatal intestinal obstruction proves to be fatal if not 
surgically corrected (Rogers, Stoltz et al. 2008, Klymiuk, Mundhenk et al. 2012). 
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The aim of this thesis was to evaluate two different approaches for the rescue of 
the lethal intestinal phenotype in CF piglets. The transgenic approach was driven 
by the idea that selective expression of CFTR in the intestine of a CF pig should 
ameliorate meconium ileus without interfering with the typical phenotype seen in 
other organ systems. The second approach focused on the finding that modifier 
genes are known to strongly influence the severity of meconium ileus in human 
CF patients. Therefore, it was evaluated whether modifier genes might also play a 
contributive role in the susceptibility for meconium ileus in CF piglets. 
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II. REVIEW OF THE LITERATURE 
1. Cystic Fibrosis 
Cystic Fibrosis (CF) is the most common lethal autosomal recessive monogenic 
disease in people from Caucasian origin with a prevalence of about 70,000 
affected individuals worldwide (Cutting 2015). Although there was no specific 
characterization of the disease until the early 20th century, historic texts give a hint 
that characteristic symptoms of the disease, like the association between elevated 
sweat levels and early death, were identified much earlier: 
Das Kind stirbt bald wieder, dessen Stirne beim Küssen salzig schmeckt. 
“The child whose brow tastes salty when kissed will soon die.” 
Almanac of Children’s Songs and Games from Switzerland (Rochholz 1857). 
In 1938, Dorothy Anderson was the first to describe in detail the clinic and 
pathology of infants suffering from neonatal intestinal obstruction and intestinal 
and respiratory complications. Due to the characteristic histology of the pancreas 
with cyst-like dilated and obstructed acini and ducts surrounded by fibrotic tissue 
she named this disease Cystic Fibrosis (Anderson 1938). 13 years later, Kessler 
(1951) hypothesized, observing that CF patients were more susceptible to heat 
prostration and sweat depletion, that exocrine glands in CF patients were 
inadequate in function. This lead to the insight that the electrolyte transport is 
disturbed and that CF patients show elevated sodium and chloride levels in sweat 
(di Sant'Agnese, Darling et al. 1953), resulting in the development of the “sweat 
test” as a valuable diagnostic tool for CF, which is still in common use today. In 
doing so, sweating is stimulated by pilocarpine iontophoresis and sodium and 
chloride concentrations can be measured in the collected sweat (Gibson and 
Cooke 1959). This major diagnostic breakthrough did not result in a better 
understanding and therapy of CF until 1989, when Riordan, Rommens et al. 
(1989) identified the underlying genetic cause of CF, i.e. mutations in the gene 
encoding the anion channel Cystic Fibrosis Transmembrane Conductance 
Regulator (CFTR). 
II. Review of the literature     4 
1.1. Genetics of Cystic Fibrosis 
The CFTR gene is located on chromosome 7, consists of 27 exons spanning about 
250 kb and encodes the CFTR anion channel. CFTR is a unique member of the 
ATP-binding cassette (ABC) family of membrane transport proteins (Riordan 
2005), playing an important role in the chloride and bicarbonate transport across 
epithelia. The CFTR protein comprises 1,480 amino acids, is predominantly 
expressed at the apical membrane of epithelial cells (Marino, Matovcik et al. 
1991, Denning, Ostedgaard et al. 1992) and occupies five functional domains – 
two membrane-spanning domains (MSD1 and MSD2) forming the actual channel 
through the membrane, two asymmetric nucleotide-binding domains (NBD1 and 
NBD2) regulating the gating of the channel by binding and hydrolysis of ATP, 
and the R-domain that mediates channel activity by cAMP-dependent 
phosphorylation (Sheppard and Welsh 1999). Up to 2,000 mutations in the CFTR 
gene have been reported to the CFTR mutation database. The most common 
mutation F508del, characterized by a deletion of phenylalanine at position 508, is 
found on at least one allele of 85 % of CF patients (Bell, De Boeck et al. 2015, 
Cystic Fibrosis Mutation Database 2015). Based on the functional effect on the 
CFTR protein, mutations are currently classified into six distinct groups (Welsh 
and Smith 1993). Mutations leading to deficient protein synthesis, like premature 
stop codons, frameshifts or nonsense mutations, are summarized in class I, 
whereas mutations in class II, amongst them the F508del mutation, lead to a 
failure in protein processing and subsequent degradation of the protein by cell 
quality control mechanisms in the endoplasmatic reticulum. In class III, mutations 
leading to alterations in the regulation of gating by failure to respond to cAMP 
stimulation are combined. Mutations of these first three classes produce the 
classic CF phenotype. In contrast, mutations of classes IV to VI often cause 
milder disease patterns due to defective chloride conductance (class IV), altered 
stability of mRNA (class V) or decreased stability of the mature protein (class VI) 
(Proesmans, Vermeulen et al. 2008, Amaral and Farinha 2013). 
II. Review of the literature     5 
1.2. Pathophysiology of Cystic Fibrosis  
CFTR does not only play an important role in the chloride and bicarbonate 
transport across epithelia, but also regulates the electrolyte transport of other 
channels via osmolar interaction. E.g., sodium absorption via the epithelial 
sodium channel ENaC and chloride efflux via the outwardly rectifying chloride 
channel ORCC are inhibited as a consequence (Reddy, Light et al. 1999, Reddy 
and Quinton 2001). The exact mechanism of how the dysfunction of CFTR leads 
to a disease that affects a range of different organs still remains unclear. However, 
the major outcome, the secretion by exocrine glands in the airways, intestine and 
pancreas with increased viscosity, decreased volume and lowered pH, is 
indisputable. Two main prevalent theories, the “high salt” and the “low volume” 
hypothesis try to answer the question of how the pathology of respiratory disease 
is exactly evoked. The “high salt” hypothesis focuses on the idea that reduced 
chloride conductance leads to an increase of NaCl in the airway surface liquid 
(ASL) that inhibits a naturally secreted antimicrobial protein and therefore 
predisposes for the development of infections (Goldman, Anderson et al. 1997). 
In contrast, the “low volume” theory claims that defective chloride secretion leads 
to less water efflux due to an osmotic gradient that is further intensified by the 
above-mentioned influences on other ion channels. The consequence is a liquid 
depletion on the epithelial surface causing an increase in viscosity of epithelial 
secretions that interferes with the function of different organs by damaging tissue 
and eventually destroying the organ (Boucher 2007, Ratjen 2009). In support of 
the “low volume” theory, studies have shown that ASL of healthy and CF 
individuals do not differ in the concentration of sodium and chloride (Knowles, 
Robinson et al. 1997) and that ASL volume is indeed reduced in CF airway 
epithelia (Matsui, Grubb et al. 1998).  
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1.3. Phenotypical abnormalities in Cystic Fibrosis 
Cystic Fibrosis is a multisystemic disease affecting the airways, the 
gastrointestinal tract including the hepatobiliary system and pancreas, the 
reproductive tract and the sweat glands. The majority of CF patients die of 
pulmonary insufficiency associated with bronchial infections (Bell, De Boeck et 
al. 2015). The depletion of ASL causes disturbances in the mucociliary clearance 
leading to an increased deposit of infectious agents in the lungs. The consequence 
is a vicious circle of chronic inflammatory and obstructive processes like 
bronchiectasis and chronic infections with a predominance of Staphylococcus (S.) 
aureus and Pseudomonas (P.) aeruginosa in the lungs and sinuses (Proesmans, 
Vermeulen et al. 2008). The genesis of the inflammation in the airways still 
remains unclear. It is controversially debated whether inflammation is a 
consequence of infection or occurs primarily in the absence of infectious agents 
(Heijerman 2005). Regardless of the precise mechanism of pathogenesis, the end 
stages of airway disease are characterized by a series of pulmonary exacerbations 
leading to a decline in lung function and an increase in respiratory and systemic 
symptoms, resulting in fatal respiratory failure (Rosenfeld, Emerson et al. 2001). 
About 10-20 % of all CF newborns suffer from meconium ileus (MI), a life-
threatening obstruction of the intestine by fetal faeces, which is treated either 
conservatively by enemas or by surgical intervention. MI can be classified into 
simple and complex forms, the latter being complicated by additional intestinal 
abnormalities such as atresia or microcolon. Depending on the severity of MI, 
surgical methods range from simple enterostomy to resection of intestinal 
segments. Interestingly, although undergoing complicated surgical interventions, 
prolonged hospitalization and being infected with P. aeruginosa earlier, the long-
term prognosis of CF patients presenting with MI is not affected negatively 
(Kappler, Feilcke et al. 2009). The prevalence of MI at birth shows a high 
correlation with more severe mutations like F508del and predisposes patients to 
develop the distal intestinal obstruction syndrome (DIOS) in later life (Kelly and 
Buxbaum 2015).  
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Another feature strongly associated with more severe mutations is pancreas 
insufficiency that occurs in 85 % of CF patients. Exocrine pancreas dysfunction 
(EPI) caused by extensive structural damage of the ducts and acini leads to 
general malnutrition, growth retardation and fat-soluble vitamin deficiency. The 
treatment by substitution of vitamins and pancreatic enzymes is well established. 
CF patients are also predisposed to develop pancreatitis and CF-related diabetes 
(CFRD), which is known to contribute to the progression of respiratory disease 
(Katkin and Schultz 2010, Brennan and Schrijver 2016). Early insulin therapy 
improves the lung function and is also associated with better weight gain 
(Hameed, Jaffé et al. 2015). 
With improved life expectancy of CF patients, liver disease characterized by focal 
biliary cirrhosis (FBC), cholangiectasis, cholelithiasis and fatty liver has become 
the second most life-threatening feature after respiratory failure (Efrati, Barak et 
al. 2003). FBC is commonly treated by oral supplementation of the bile salt 
ursodeoxycholic acid that normalizes liver function. Only if hepatobiliary disease 
is complicated by portal hypertension, a liver transplantation is considered (Kelly 
and Buxbaum 2015).  
All males with classic CF suffer from infertility due to the congenital bilateral 
absence of the vas deferens (CBAVD) and obstructive azoospermia. In contrast, 
only a small percentage of women affected exhibit reduced fertility, however, 
without any signs of structural abnormalities (O'Sullivan and Freedman 2009). It 
is of note that even men carrying only one mutation or being diagnosed with 
atypical CF without any other characteristic symptoms, are at high risk to suffer 
from CBAVD or other fertility problems (Mak, Zielenski et al. 1999). 
1.4. Diagnosis of Cystic Fibrosis 
As mentioned above, the gold standard for the diagnosis of CF in patients 
exhibiting clinical signs or symptoms is still the sweat test developed by Gibson 
and Cooke (1959). If chloride concentrations are greater than 60 mmol/L, a 
definitive diagnosis of CF can be reached, whereas intermediate concentrations 
between 30-59 mmol/L are only indicative of CF. In such cases, CF can only be 
diagnosed by identifying two CF-causing mutations on both alleles. Even for 
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patients with diagnostic chloride concentrations, a screening for mutations by 
molecular testing is commonly conducted. In order to detect CF patients before 
showing any clinical signs, a newborn screening for CF was established in over 40 
states worldwide. Immunoreactive trypsinogen (IRT), an enzyme elevated by 
pancreatic injury and therefore indicative of CF, is routinely measured in the 
blood of newborns. If abnormal levels are detected, further tests such as mutation 
screening or sweat tests are performed to confirm the diagnosis of CF (Farrell, 
Rosenstein et al. 2008, O'Sullivan and Freedman 2009). In days of powerful 
molecular-genetic tools, screening for mutations in the CFTR gene can be 
conducted easily. Generally, a panel of 23 mutations known to cause classic CF 
and occurring with a frequency of more than 0.1 % in CF patients’ chromosomes, 
is screened for by commercially available analyte specific reagents (Strom, 
Janeszco et al. 2006). In the event that mutations cannot be identified by this 
method, an additional assay is conducted. By sequencing all exons, splice 
junctional sequences, the promoter and parts of intron 11 and 19, 98.7 % of all 
reported mutations are detected (Strom, Huang et al. 2003).  
1.5. Treatment strategies for Cystic Fibrosis 
Although the causative agent of CF has been discovered more than 25 years ago, 
treatment is still focused on symptomatic therapy. For an effective treatment, 
close monitoring and early and aggressive intervention is recommended to fulfil 
the primary goals – maintaining good lung function as long as possible, assuring 
adequate growth and managing CF-related complications. As good nutritional 
status is strongly correlated with improved pulmonary function (Konstan, Butler 
et al. 2003), it is essential for CF patients with pancreatic insufficiency to keep a 
balanced, high-caloric diet with supplementation of fat-soluble vitamins and 
pancreatic enzymes (Borowitz, Baker et al. 2002). Management of respiratory 
problems depends on the different stages of CF lung disease – from airway 
clearing techniques and mucolytic inhalation in the pre-infectious status to 
aggressive intravenous and aerosol antibiotic treatment and eventual lung 
transplantation in the end stage (Davies, Alton et al. 2007). In the case of CFRD 
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and hepatobiliary disease, additional medication with insulin and ursodeoxycholic 
acid, respectively, is recommended (Kelly and Buxbaum 2015). 
Over the last decades, efforts in the multidisciplinary symptomatic treatment have  
improved the survival age from early childhood in the 1950s to a median survival 
age of 37 years today (Cutting 2015). Nevertheless, novel therapeutic approaches 
with the aim of curing the disease by restoring the CFTR function have only 
evolved recently. 
Gene therapy approaches for CF are based upon the concept of gene 
complementation, meaning that an additional WT CFTR cDNA copy is delivered 
to CF-affected cells, an approach feasible for CF patients with any genetic 
mutation (Gill and Hyde 2014). First results from clinical phase IIB trials with the 
non-viral, liposome-based vector GL67A indicate that gene therapy can lead to an 
improvement in lung function (Alton, Armstrong et al. 2015). 
Another therapeutic approach is the development of novel drugs, the so-called 
CFTR modulators, which target specific mutation classes directly (Amaral and 
Kunzelmann 2007). “Suppressors” are suitable for mutations of class I by 
promoting the read-through of premature stop codons and thereby permitting the 
translation of the full-length protein. Ataluren has been successfully used in 
clinical phase III trials, showing a beneficial effect on lung function, but can only 
be used for the 5 % of CF patients carrying class I mutations (Wilschanski, Miller 
et al. 2011). “Correctors” act as chaperones by allowing the mutant protein to 
escape degradation and reach the cell membrane and are therefore suitable for 
class II mutations. Treatment of CF patients carrying the most common F508del 
mutation with the corrector Lumacaftor alone is insufficient, whereas in 
combination with the potentiator Ivacaftor it is now a commercially available drug 
approved by the US Food and Drug Administration (FDA) (Cystic Fibrosis 
Foundation 2016). “Potentiators” increase channel gating activity and are used for 
the treatment of class III mutations (Clancy and Jain 2012, Bell, De Boeck et al. 
2015, Brennan and Schrijver 2016). The potentiator Ivacaftor, the first FDA-
approved molecular therapeutic for CF, can be successfully used in the treatment 
of about 3 % of CF patients that carry the G551D mutation by increasing chloride 
transport through improved channel activity (Van Goor, Hadida et al. 2009).  
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2. Animal models of Cystic Fibrosis 
Animal models are a unique tool for a better understanding of the 
pathophysiological mechanisms in Cystic Fibrosis and the development or testing 
of new therapeutic approaches. Among other things, they allow for the study of 
early pathogenesis prior to clinical manifestations and the controlled evaluation of 
therapeutic effects. The relevance of a disease model increases if a systematic 
comparison of different model species is possible (Olivier, Gibson-Corley et al. 
2015). The rapid technological progress in the genetic manipulation of animals in 
the last decades (Whitelaw, Sheets et al. 2016) has facilitated the efficient 
development of animal models for Cystic Fibrosis in five different species, a 
unique feature among human genetic disorders (Cutting 2015). Each of these 
model organisms has its specific advantages, but also major limitations. 
2.1. Cystic Fibrosis mice models 
Historically, the first animal model for CF was the CF mouse model. Mice models 
bear several advantages – methods for genomic manipulation are well established, 
the reproduction rate is high and the costs of maintaining and housing are low. 
Since the first mouse strain carrying a mutation in the Cftr gene was generated in 
1992 (Snouwaert, Brigman et al. 1992), at least 14 different CF mouse models, 
carrying null and clinically relevant mutant Cftr forms like F508del, were 
developed (Scholte, Davidson et al. 2004, Fisher, Zhang et al. 2011). Gene 
targeting approaches as well as environmental influences cause slight variations in 
the severity of the phenotype, but there is consensus in the important phenotypical 
abnormalities (Davidson and Rolfe 2001, Wilke, Buijs-Offerman et al. 2011). The 
most prominent hallmark feature in CF mice is the severe intestinal phenotype 
characterized by electrophysiological abnormalities, mucus accumulation in the 
dilated crypts, goblet cell hyperplasia, a general failure to thrive and death around 
weaning due to intestinal obstruction. The physiological processes involved in the 
intestinal blockage are reminiscent of the MI complications in human CF infants, 
but advance differently from the clinical point of view (Guilbault, Saeed et al. 
2007). In general, pancreatic insufficiency is clearly less pronounced than in 
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human CF patients, probably because of a relatively low expression of CFTR in 
the murine pancreatic ducts and the existence of an alternative calcium-activated 
fluid secretory pathway (Gray, Winpenny et al. 1995). Another feature absent in 
CF mice is obvious liver pathology. However, the murine CF gallbladder shows 
abnormalities like distension, inflammatory processes or an obstruction with 
vicious bile leading to emptying defects (Debray, Rainteau et al. 2012). An 
interesting feature in CF mice is that a lack of CFTR leads to abnormalities in 
enamel development in the incisors (Wright, Kiefer et al. 1996). Although most of 
the male CF mice exhibit reduced fertility, the complete bilateral absence of the 
vas deferens typical for humans is missing probably due to the presence of 
additional electrolyte transport mechanisms in the reproductive tract (Leung, 
Wong et al. 1996) . The main problem limiting the usage of the mouse as an 
animal model for CF is the absence of the respiratory disease typical for human 
CF. Although CF mice show some distinct pathological abnormalities like defects 
in mucociliary clearance or pulmonary parenchymal thickening, they neither 
develop spontaneous chronic infection nor inflammation of the lung. The reasons 
for this discrepancy still remain unclear, but potential explanations could be 
differences in the distribution of secretory cells and submucosal glands or the 
existence of alternative chloride channels (Grubb, Paradiso et al. 1994, Grubb and 
Boucher 1999). 
In conclusion, CF mouse models have given important insights into disease 
mechanisms, like the role of alternative secretory pathways or potential modifier 
genes and the pathology of intestinal disease. They allow for the evaluation of 
novel therapeutic approaches, but due to their deficiency of recapitulating human 
airway disease, other model species are essential for CF research. 
2.2. Cystic Fibrosis rat model 
In 2014, the first Cftr-/- rat was generated by genome editing with Zinc finger 
nucleases. Advantages of the rat as a model species for CF are the fast 
reproduction rate, and, unlike mice, a distribution pattern of submucosal glands in 
the airways comparable to humans and a size allowing for surgical interventions 
and easier tissue collection. Similar to CF mice, Cftr-/- rats show a failure to thrive 
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with decreased survival at weaning because of intestinal obstruction and abnormal 
enamel deposition in teeth, but no obvious signs of hepatobiliary or pancreatic 
changes. Histological changes in the intestine include cell sloughing, mucus-
dilated crypts and bacterial overgrowth. Short-circuit measurements by Ussing-
chamber confirm the absence of CFTR in the intestine. Similar to human CF, 
male CF KO rats exhibit bilateral absence of the vas deferens and abnormalities in 
the airways like reduced tracheal circumference and reduced submucosal gland 
area. Unfortunately, the lungs appear normal without any signs of pathological or 
inflammatory processes (Tuggle, Birket et al. 2014). 
2.3. Cystic Fibrosis ferret model 
Since the structure of the airways resembles humans and the ferret lung is a 
known disease model for lung infections, the ferret is considered to be a 
promising model species for CF. Ferrets that are heterozygous for a disruption of 
the CFTR gene were generated by recombinant Adeno-associated virus -mediated 
(rAAV) gene targeting (Sun, Yan et al. 2008) and selectively bred for the 
production of litters containing WT, CFTR+/- and CFTR-/- kits (Sun, Sui et al. 
2010). CF KO kits suffer from lethal MI with a penetrance of 75 %, but even 
ferrets that are able to remove MI on their own fail to thrive and die within a few 
days if not reared with a mixture of oral laxatives, proton pump inhibitors, 
antibiotics and pancreatic enzyme supplementation. Surviving CF kits exhibit 
crypts dilated by vicious mucus, villous atrophy, lymphoplasmacytic 
inflammation and bacterial overgrowth of the intestine. Although the 
hepatobiliary system appears normal at birth, gallbladder disease with mucous 
changes and mucosal proliferation occurs in CF KO ferrets older than one month. 
Additionally, liver enzymes are elevated, indicating early functional liver disease 
(Sun, Olivier et al. 2014). CF KO kits are born with only mild signs of exocrine 
pancreatic disease and slight abnormalities in endocrine function. However, 
during the first months a progressive destruction and remodeling of the exocrine 
and endocrine tissue occurs and ferrets develop exocrine pancreatic insufficiency 
and characteristics of CF-related diabetes (Olivier, Yi et al. 2012). In all male CF 
KO ferrets, the vas deferens is either completely absent or degenerated (Sun, Sui 
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et al. 2010). Most importantly, ferrets develop lung disease very similar to 
humans with a high susceptibility to bacterial infections, impaired mucociliary 
clearance and characteristic histological changes like mucus-obstruction of the 
airways and submucosal glands, atelectasis and inflammation (Sun, Olivier et al. 
2014). 
2.4. Cystic Fibrosis zebrafish model 
A model organism principally used for the examination of early developmental 
effects of Cftr is the zebrafish. Studies on cftr knockdown zebrafish embryos 
show that bacterial clearance after P. aeruginosa infection is clearly reduced in 
comparison to other pathogens commonly isolated in CF patients, indicating a 
Cftr-mediated specific resistance to P. aeruginosa (Phennicie, Sullivan et al. 
2010). Other important insights gained from zebrafish cftr mutants generated by 
TALENs are the important role of Cftr in the regulation of fluid secretion into the 
Kupffer’s vesicles - thereby affecting left-right asymmetry (Navis, Marjoram et 
al. 2013) - and the fact that pancreatic destruction occurs without major defects in 
the early organ development (Navis and Bagnat 2015). 
2.5. Cystic fibrosis pig models 
Genetically-engineered pigs harbor great potential for use in biomedical and 
translational research as they share many important features with humans. The 
similarity in terms of anatomy, physiology, histology, immunology, metabolism 
and also genomics is high, the short generation time and large litter size facilitate 
rapid production of enough animals and environmental influences can be 
standardized. Additionally, the porcine lifespan allows for long-term studies 
regarding effects of therapeutic treatments and pathogenesis, and the body size 
allows for testing of human devices and surgical interventions as well as efficient 
and easy tissue collection (Rogers, Abraham et al. 2008, Aigner, Renner et al. 
2010).  
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To date, three different porcine CF models either carrying a completely disrupted 
CFTR gene (Rogers, Stoltz et al. 2008, Klymiuk, Mundhenk et al. 2012) or the 
most common human mutation F508del (Rogers, Hao et al. 2008) have been 
generated by different genetic approaches. Rogers and coworkers targeted the 
CFTR locus in fetal fibroblasts by using rAAV vectors, followed by somatic cell 
nuclear transfer (SCNT) and embryo transfer, resulting in male heterozygous 
CFTR+/- offspring that was bred selectively over two generations to generate 
CFTR-/- piglets. The first European CF pig model was established by Klymiuk, 
Mundhenk et al. (2012) via sequential targeting of the CFTR locus in primary 
kidney cells using large vectors based on modified bacterial artificial 
chromosomes (BACs). 
CF pigs show many of the characteristic phenotypic abnormalities found in 
human CF patients. Exocrine pancreas destruction in newborn piglets is 
histopathologically characterized by small, degenerated lobes with a decreased 
number of acinar cells, dilated ducts filled with eosinophilic material and signs of 
mild inflammation, surrounded by undifferentiated connective tissue (Meyerholz, 
Stoltz et al. 2010, Klymiuk, Mundhenk et al. 2012). Although the endocrine 
pancreatic tissue seems morphologically normal at birth, neonatal CF pigs exhibit 
functional abnormalities in glycaemic regulation and insulin secretion and, 
according to human CFRD, they tend to spontaneously develop hyperglycemia. 
This observation refuted the long-standing hypothesis that endocrine changes are 
mainly caused by the destruction of the exocrine pancreas (Uc, Olivier et al. 
2015). Human focal biliary cirrhosis is mirrored in the CF piglet in a milder form 
with hyperplastic bile ducts surrounded by fibrotic tissue and chronic cellular 
inflammation. Gallbladder disease is reported in 15-30 % of human CF patients, 
but is a consistent finding in CF piglets, which have a micro-gallbladder 
obstructed by viscous bile and mucus and signs of epithelial proliferation (Welsh, 
Rogers et al. 2009). Pancreatic and biliary secretions are altered in terms of 
volume, pH and content of enzymes, suggesting an involvement in disease 
pathogenesis (Uc, Giriyappa et al. 2012).  
II. Review of the literature     15 
CF piglets also exhibit another feature commonly found in human male CF 
patients, i.e. a degenerated or absent vas deferens sometimes accompanied by 
epididymis atresia without tubular structures (Pierucci-Alves, Akoyev et al. 
2011). Similar to CF ferrets, CF piglets show a defect in the mineralization of 
enamel, suggesting an important role of CFTR in the maturation and bioformation 
of enamel (Chang, Lacruz et al. 2011). A very interesting finding is that the 
absence of CFTR leads directly to defects in the peripherous nervous system, a 
feature that is known from human CF patients but was thought to be caused by the 
secondary manifestations of the disease (Reznikov, Dong et al. 2013). 
2.5.1. The value and uniqueness of the porcine CF model regarding the 
respiratory phenotype 
Concerning pulmonary disease, the pig bears several advantages over other model 
species. The porcine lung has been an established model for both the healthy and 
sick human lung and therefore has been commonly used for the evaluation of 
pulmonary therapeutics long before CF pig models have been established (Rogers, 
Hao et al. 2008). The anatomy, histology and morphology of the human and 
porcine airways show great levels of similarity (Judge, Hughes et al. 2014). Lung 
structure, tissue modeling, volume and vascular circulation are comparable, and 
the distribution pattern of submucosal glands throughout the cartilaginous airways 
and the secretory functions that are known to affect the pulmonary phenotype in 
CF (Widdicombe and Wine 2015) resemble those in humans. Physiological and 
biochemical processes important for CF pathogenesis like transepithelial 
electrolyte transport or mucociliary clearance are reported to lay in the same range 
in humans and pigs, and in general, the porcine lung is susceptible to infection by 
CF-relevant human pathogens like P. aeruginosa or S. aureus (Rogers, Abraham 
et al. 2008). Another important factor for the study of infection and inflammation 
in CF patients is the role of the porcine innate immune system in inflammatory 
processes that shows great parallels to humans (Bréa, Meurens et al. 2012). The 
characterization of cellular and tissue expression patterns of porcine CFTR both 
on mRNA and protein level revealed that the distribution is similar to humans in 
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all major CF-relevant organ systems, supporting the suitability of the pig for CF 
research (Plog, Mundhenk et al. 2010). 
Taken together, it does not surprise that, in contrast to most other animal models, 
CF piglets exhibit several phenotypic abnormalities in the airways. At birth, the 
lungs and submucosal glands appear morphologically normal and show no signs 
of infection or inflammation (Rogers, Stoltz et al. 2008), whereas the tracheas are 
misshapen with thickened cartilage and enlarged smooth muscle bundles 
(Klymiuk, Mundhenk et al. 2012). Similar to human CF, neonatal piglets have 
hypoplastic sinuses and spontaneously develop chronic infection (Chang, Pezzulo 
et al. 2012). Like human CF patients, CF pigs suffer from lung disease 
characterized by inflammation, remodeling of tissue and accumulation of mucus 
accompanied by defects in the eradication of bacteria (Stoltz, Meyerholz et al. 
2010). 
A range of important insights into the molecular mechanisms involved in CF 
pathogenesis have been gained on CF pigs or porcine CF tissue. Experiments on 
early pathogenesis of lung disease show that anatomical defects in the airways 
caused by a lack of CFTR might contribute to the onset of respiratory disease. The 
detection of sinus hypoplasia in newborn CF piglets prior to CF-related sinusitis 
could clear up the question whether sinus hypoplasia in human CF patients results 
out of chronical infectious processes or is a developmental consequence of lack of 
CFTR (Chang, Pezzulo et al. 2012). Inspired by the finding that CF piglets show 
structural abnormalities of the trachea, it was demonstrated by CT scans in CF 
infants and by sonography in adult CF patients that similar features are present in 
humans (Meyerholz, Stoltz et al. 2010, Diwakar, Adam et al. 2015). The 
hypothesis that air trapping and airway obstruction in human CF patients are 
mainly secondary consequences of infection and inflammation was refuted due to 
the fact that newborn piglets develop these features spontaneously in the absence 
of inflammatory processes. A potential explanation for these findings is the 
reduction in size of the proximal airways (Adam, Michalski et al. 2013). Another 
indication for the contribution of structural airway defects to early disease 
pathogenesis was given by the fact that structural abnormalities lead to irregular 
particle distribution and increased particle deposition in the porcine lung 
(Awadalla, Miyawaki et al. 2014). In addition, the porcine CF model has enabled 
some breakthrough studies on the genesis of inflammation and infection in CF. 
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CF piglets show no evidence of inflammatory processes in the lung until they 
become infected as a result of impaired eradication of bacteria, indicating that 
infection is the causative agent that triggers inflammation and not vice versa 
(Stoltz, Meyerholz et al. 2010). A possible explanation for defective eradication 
of bacteria in the porcine CF lung is given by Pezzulo, Tang et al. (2012). They 
postulate that decreased pH of the airway surface liquid, caused by defective 
HCO3
- secretion, leads to impairment in the killing of pathogens. Hoegger, 
Fischer et al. (2014) demonstrated that besides defects in the secreted 
antimicrobial activity, a second important lung defence mechanism, the 
mucociliary transport (MCT), is disturbed. Primary MCT defects occur 
independently from depleted airway surface liquid due to impaired detachment of 
mucus strands from submucosal glands, a feature that might be mediated by the 
absence of bicarbonate transport (Birket, Chu et al. 2014). Studies on explanted 
tracheas from CF and WT piglets demonstrate that incubation with CF-relevant 
pathogens triggers CFTR-dependent ASL-secretion, a feature that would be 
lacking in CF patients, thereby facilitating infectious processes (Luan, 
Campanucci Vó et al. 2014). Most importantly, studies on electrolyte transport in 
porcine CF airway tissue have questioned the long-standing hypothesis that 
sodium absorption is enlarged and periciliary liquid depth is reduced in CF 
epithelia. Results indicate that HCO3
- and Cl- transport are the main pathways 
disturbed by the loss of CFTR function without any alteration in sodium 
absorption (Chen, Stoltz et al. 2010), a concept that could be confirmed by 
experiments on human airway epithelia (Itani, Chen et al. 2011). First trials 
supporting the role of the CF pig for in vivo testing of new therapeutic approaches 
have been performed using adenovirus-mediated gene transfer to correct ion 
transport in porcine CF sinus epithelia (Potash, Wallen et al. 2013). 
2.5.2. The lethal intestinal phenotype impairs the utility of the CF pig 
model – approaches to overcome this limitation 
The most prominent feature in CF piglets is intestinal disease with fatal meconium 
ileus. In contrast to CF infants who suffer from MI in about 15 % of all cases, MI 
in CF piglets occurs with a prevalence of 100 %. The site of obstruction with fetal 
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faeces and mucus ranges from the distal part of the jejunum to the beginning of 
the spiral colon. An atretic and stenotic microcolon with reduced diameter and 
pliability is found distal to the site of obstruction. MI proves to be fatal within 24-
36 h after birth if it is not corrected surgically by ileostomy or cecostomy, as 
piglets develop severe enteritis and peritonitis or even perforation of the intestine 
(Stoltz, Meyerholz et al. 2010). Rather than influences of the abnormal pancreas, 
the primary cause for this intestinal blockage is the primary lack of CFTR in the 
intestine (Stoltz, Rokhlina et al. 2013). Another intestinal lesion found in CF pigs 
is diverticulosis at the mesenterial side of the jejunum distended with meconium, 
caused by herniation of the tuna mucosa and submucosa through the hypertrophic 
tuna muscularis, predisposing the intestine to rupture (Meyerholz, Stoltz et al. 
2010, Klymiuk, Mundhenk et al. 2012). Both of these pathological findings are 
also reported in human CF patients, however, with a lower incidence rate and less 
severity. Histopathological findings include the obstruction of duodenal glands 
with mucus, atrophy of the epithelium and mucinous hyperplasia that is more 
pronounced in the intestine distal to the site of obstruction, whereas no obvious 
signs of primary inflammation are found (Meyerholz, Stoltz et al. 2010). 
In conclusion, pathological findings in all porcine CF models strongly resemble 
the pathology found in human CF patients, thereby making the porcine CF pig an 
ideal model organism for CF research. However, the CF pig is hampered by the 
fatal intestinal obstruction with meconium. Although many studies can be 
performed on tissue or cell cultures derived from neonatal CF piglets, an essential 
aspect of an ideal model organism is that it can reach adulthood and thereby 
allows for long-term studies regarding pathogenesis and evaluation of potential 
therapies. To overcome the lethal intestinal obstruction in CF piglets, several 
approaches from different kind of scientific views are imaginable or have already 
been tried.  
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Surgical approach 
As mentioned above, MI is also a feature that occurs in about 15 % of human CF 
newborns and has to be treated vigorously to assure survival (van der Doef, 
Kokke et al. 2011). Depending on the severity of MI, therapeutic options range 
from initial treatments with enemas using gastrografin or N-acetyl-cystein to 
complex abdominal surgeries like anastomosis or enterostomy (Karimi, Gorter et 
al. 2011). In CF piglets, non-surgical treatment with laxatives alone is not enough 
to rescue the severe intestinal phenotype. To ensure their survival, they have to 
undergo ileostomy or cecostomy to bypass the obstruction. Perioperatively, 
piglets have to be treated supportively with intravenous fluids, analgesics and 
prophylactic antibiotics (Stoltz, Meyerholz et al. 2010). However, surgical 
correction of the MI is associated with a high rate of postoperative mortality in 
piglets; one of the reasons could be the long time between birth and surgery that is 
needed to obtain genotyping results. In order to shorten this interval, Guillon, 
Chevaleyre et al. (2015) have developed a new rapid method for the identification 
of CF piglets via CT scan. It has to be said, however, that a surgical correction is 
sometimes not feasible due to atretic parts of the large intestine and that very high 
surgery- and intensive care-related costs hinder the production of living CF piglets 
on a routine basis via this approach. 
Transgenic approach 
The idea to rescue the severe intestinal phenotype in CF animals by transgenic 
expression of CFTR under the control of a gut-specific promoter is not new. The 
transgenic CFTR protein is selectively expressed in the intestine, thereby 
correcting the obstructive phenotype that is caused by the lack of CFTR, and in no 
other organ systems. Therefore, transgenic CF animals should exhibit all the 
characteristic features of CF apart from intestinal disease. Already in 1994, Zhou, 
Dey et al. demonstrated that expression of human CFTR, driven by a rat fatty-acid 
binding protein promoter, corrected the lethal obstructive phenotype in CF mice 
and restored chloride secretion (Zhou, Dey et al. 1994). This concept was 
confirmed by Ostedgaard, Meyerholz et al. (2011) for a truncated CFTR protein, 
which might be applied by viral gene therapy. A transgenic approach also works 
for the porcine CF model, as piglets with selective expression of CFTR under the 
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control of the rat fatty-acid binding protein promoter are able to survive 
meconium ileus and develop lung disease and other typical organ manifestations 
over time. An expression rate of about 20 % of WT CFTR seems to be sufficient 
to rescue the intestinal phenotype; however, piglets still have to be treated 
supportively with gastrografin enemas to ensure survival (Stoltz, Rokhlina et al. 
2013). 
Contribution of genetic modifiers to disease severity 
Studies on monozygotic and dizygotic human CF twin pairs have demonstrated 
that disease severity shows higher concordance in homozygous twins. This 
implies that the phenotypic manifestation of the basic mutation is influenced by 
additional genetic factors, so-called modifier genes (Bronsveld, Mekus et al. 
2001). It is now known that modifier genes contribute to the variability of several 
features in CF – severity of obstructive lung disease, establishment of chronic 
infection with P. aeruginosa, risk for development of CFRD, low BMI and also 
neonatal MI (Cutting 2015). The heritability both for developing MI and the 
absence of MI is estimated to be 1.0. This finding indicates the high contribution 
of modifier genes responsible for increased susceptibility to MI as well as 
protection against MI (Blackman, Deering-Brose et al. 2006). Genome-wide 
analysis has revealed several potential candidate regions, including 
polymorphisms in the genes coding for several members of the solute transport 
family of proteins, SLC4A4, SLC6A14 and SLC26A9 (Dorfman, Li et al. 2009, 
Sun, Rommens et al. 2012). SNPs in the MSRA gene coding for the methionine 
sulfoxide reductase have a protective effect against MI, a hypothesis supported by 
the fact that mice lacking MSRA expression do not show the typical intestinal 
obstruction around weaning (Henderson, Doshi et al. 2012). 
The high contribution of modifier genes to intestinal obstruction in humans and 
murine CF models permits the assumption that intestinal disease severity in CF 
pigs might also be modified. It has to be mentioned that there is no knowledge 
about the existence of modifier genes in the porcine genome that might modulate 
the CF phenotype. In addition, insights about potential candidate genes occurring 
in mice and humans cannot be directly adapted to the pig. 
One of the possible candidate genes in the porcine genome is the CLCA4b gene 
encoding a member of the calcium-activated chloride channel regulator protein 
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family. In CF humans, CLCA4 is known to modify the intestinal phenotype by 
modulation of residual chloride conductance (Kolbe, Tamm et al. 2013). A 
species-specific duplication of the corresponding pCLCA4 gene occurs in the pig. 
In contrast to CLCA4a, CLCA4b is selectively expressed in small and large 
intestine epithelial crypts that are the only intestinal cell type to express CFTR, 
suggesting a potential involvement in the modulation of MI. In addition, a 
deleterious mutation in the CLCA4b gene occurs naturally with a high prevalence 
in the pig population without obviously affecting the phenotype in WT animals. 
This might be caused by the fact that carriers of this deletion bear a selective 
advantage over other animals (Plog, Klymiuk et al. 2015). 
The aim of my thesis was to find a way to increase the life expectancy of the 
porcine CF model by evaluation of two different approaches to overcome the 
lethal intestinal phenotype in CFTR-/- piglets. In the first part of this study the 
impact of transgenic expression of CFTR in the intestine on the severity of 
meconium ileus in CFTR-/- piglets is examined with a special focus on expression 
analysis of CFTR and the gut-specific promoter FABP2 at mRNA level. In 
addition, the porcine CF model is further characterized both at genomic and 
protein level. The second part of my thesis focuses on the role of modifier genes 
in the development of meconium ileus in CFTR-/- piglets. The influence of the 
candidate gene CLCA4b on meconium ileus is investigated and other candidate 
loci with a potential impact on the intestinal phenotype are screened for by a 
genome-wide analysis. In addition, mucociliary transport mechanisms in CF KO 
and WT piglets are examined. 
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III. ANIMALS, MATERIALS AND METHODS 
1. Animals 
The animals included in this work were wild type (WT), heterozygous CFTR+/- or 
homozygous CFTR-/- piglets generated by breeding of heterozygous female and 
male CFTR+/- pigs. In addition, CFTR-/- piglets carrying an additional transgene 
for the expression of CFTR under the control of the FABP2 promoter were 
produced by somatic cell nuclear transfer (SCNT) followed by embryo transfer 
(ET). These piglets are designated as gut-modified CFTR-/- piglets in the 
following. For the generation of heterozygous CFTR+/- piglets, the CFTR locus on 
one allele in primary kidney cells of a 3-months-old male WT boar was targeted 
with a bacterial artificial chromosome (BAC) vector containing large regions of 
homology. This lead to the insertion of a STOP box and neo®/kan® resistance 
cassette adjacent to the start codon in exon 1. Correctly modified cell clones were 
used for SCNT and embryos transferred laparoscopically to estrus-synchronized 
gilts (Klymiuk, Mundhenk et al. 2012). All animal experiments were approved by 
the responsible animal welfare authority (Regierung von Oberbayern, AZ 55.2-1-
54-2531-78-07, 55.2-1-54-2532-70-12 and 55.2-1-54-2532-163-2014). 
2. Materials 
2.1. Chemicals 
2-Mercaptoethanol Roth, Karlsruhe 
2-Propanol Roth, Karlsruhe 
Acetic Acid (glacial) Roth, Karlsruhe 
Acrylamide (30 %) BioRad, Munich 
Agarose UltraPureTM Invitrogen, Karlsruhe 
Albumin fraction V Roth, Karlsruhe 
AmershamTM ECLTM western blotting GE Healthcare, Munich 
detection reagent 
Ammonium persulfate (APS) BioRad, Munich 
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Bicinchoninic acid Sigma, Steinheim 
Bromophenolblue Roth, Karlsruhe and Merck, 
Darmstadt 
Chloroform (Trichloromethane) Roth, Karlsruhe 
Complete proteinase inhibitor cocktail tablets Roche Diagnostics, Mannheim 
Coomassie® Brilliant Blue G250 Merck, Darmstadt 
CuSO4 (cupric sulfate) Sigma, Steinheim 
DAB (3.3’ Diaminobenzidine tetrahydrochloride) KemEnTec, Denmark 
EDTA (Ethylenediaminetetraacetic acid) Roth, Karlsruhe and VWR, 
Darmstadt 
Ethanol Roth, Karlsruhe 
Ethidiumbromide (1 mg/mL) Merck, Darmstadt  
Formaldehyde solution, 37 % Sigma, Steinheim 
Formamide Roth, Karlsruhe 
Glycerin (Glycerol) Roth, Karlsruhe and Sigma, 
Steinheim 
Glycine Roth, Karlsruhe 
H2O2 (Hydrogen peroxide 37 %) Roth, Karlsruhe 
HCl (Hydrochloric acid 25 %) VWR, Darmstadt 
HCl (Hydrochloric acid, 37 %) Roth, Karlsruhe 
Histokitt Glaswarenfabrik Karl Hecht, 
Sondheim/Rhön  
KCl (Potassium chloride) Merck, Darmstadt 
KH2PO4 (Potassium dihydrogen phosphate) Merck, Darmstadt 
Mayer‘s Hemalum solution Merck, Darmstadt 
Methanol Roth, Karlsruhe and Sigma, 
Steinheim 
MgCl2 (Magnesium chloride) Fluka Chemie, Schweiz 
MOPS (3-(N-morpholino) propanesulfonic acid) Roth, Karlsruhe 
Na2HPO4 Merck, Darmstadt 
(Di-sodiumhydrogenphosphate-2-hydrate) 
NaCl (Sodium chloride) Merck, Darmstadt 
NaOH (Sodium hydroxide 2N) Roth, Karlsruhe and VWR, 
Darmstadt 
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Paraformaldehyde Sigma, Steinheim 
Perfadex® XVIVO Perfusion, Sweden 
Ponceau S Sigma, Steinheim 
Roti-Histofix 4 % Roth, Karlsruhe 
SDS (Sodium dodecyl sulfate)  Serva Electrophoresis, 
Heidelberg  
Sucrose Sigma, Steinheim 
SuperBlock (PBS) blocking buffer Thermo Scientific, Schwerte 
Target Retrieval Solution Dako, Hamburg 
Temed (Tetraethylethylenediamine) Roth, Karlsruhe 
Tissue-Tek® O.C.T Compound Sakura, Staufen 
Tris (Tris-(hydroxymethyl)-aminomethane) Roth, Karlsruhe 
Tri-sodium citrate dihydrate Roth, Karlsruhe 
Triton X-100 Roth, Karlsruhe 
TRIzol® Reagent Thermo Scientific, Schwerte 
Tween®20 Sigma, Steinheim 
Universal Agarose Bio&SELL, Nürnberg 
Vectashield Antifade Mounting Medium with Vector Laboratories, USA 
DAPI 
w/v nonfat dry milk (blotting grade) Roth, Karlsruhe 
Xylene VWR, Darmstadt 
Xylene cyanole Roth, Karlsruhe 
2.2. Consumables 
AmershamTM HyperfilmTM ECL GE Healthcare, Munich 
high performance chemiluminescense film 
Centrifuge tubes (15 mL, 50 mL) Falcon, Becton Dickinson, 
Heidelberg 
Cover slips for histology Roth, Karlsruhe 
Disposable plastic pipettes Falcon, Becton Dickinson, 
Heidelberg 
Disposal polypropylene bags Sarstedt AG+Co, Nümbrecht 
EDTA Monovette® blood collection system Sarstedt, Nümbrecht 
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Gel blotting paper (Whatman paper) BioRad, Munich 
Glass Pasteur pipettes Brand, Wertheim 
Immobilon®-P nitrocellulose transfer Millipore, Billerica, USA 
membranes 
LightCycler® 480 Multiwell Plates 96 Roche Diagnostics, Mannheim  
LightCycler® 480 Sealing Foil Roche Diagnostics, Mannheim 
Microscope slides Star Frost® Engelbrecht, Edermünde 
OP-Cover (60 × 90 cm) A. Albrecht, Aulendorf 
Parafilm® M American Can Company, USA 
PCR reaction tubes (0.2 mL) Brand, Wertheim 
Pipet tips Eppendorf, Hamburg 
Pipet tips with filter Thermo Scientific, Schwerte 
Prot, ElecTM tips BioRad, Munich 
SafeGrip® latex gloves SLG, Munich 
Safe-Lock reaction tubes (1.5 mL, 2 mL) Eppendorf, Hamburg 
Saran Barrier food wrap Dow, USA 
Sempercare® nitrile gloves Satra Technology Center, USA 
Tissue culture dishes (60 mm × 15 mm) Sarstedt, Nümbrecht 
Tissue culture plate, 96 well Falcon, Becton Dickinson, 
Heidelberg 
Uni-Link embedding cassettes Engelbrecht, Edermünde 
2.3. Devices 
Accu-jet® pro pipette controller Brand, Wertheim 
Agarose gel electrophoresis chamber WG - Biotech, Ebersberg and 
OWL Inc., USA 
Autotechnikon Histomaster 2050/Dl Bavimed, Birkenau 
Axiovert 200 M Zeiss, Oberkochen 
Benchtop 96 tube working rack Stratagene, USA 
Chyo Petit Balance MK-2000B YMC Co, Japan 
CryoStar NX70 Thermo Scientific, Schwerte 
Eppendorf Centrifuge 5415 D Eppendorf, Hamburg 
Eppendorf Centrifuge 5417 R Eppendorf, Hamburg 
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Eppendorf Centrifuge 5810 R Eppendorf, Hamburg 
Gel documentation system BioRad, Munich 
GeneQuant Pro spectrophotometer Thermo Scientific, Schwerte 
HM 315 microtome Microm, Walldorf 
Homogenizer ART-Micra D-8 ART, Müllheim 
Hybridization oven Bachofer, Reutlingen 
Incubator Memmert, Schwabach 
inoLab® pH meter 7110 WTW, Weilheim 
Labcycler SensoQuest, Göttingen 
LightCycler® 96 Roche Diagnostics, Mannheim 
Mastercycler® gradient Eppendorf, Hamburg 
Mettler PM 6000 Mettler - Toledo, Gießen 
Microwave DAEWOO, Korea 
Mini-Protean Tetra Cell BioRad, Munich 
Optimax X-ray Film processor 1170-1-0000 PROTEC, Oberstenfeld  
Pipettes (1000 µL, 200 µL, 20 µL, 10 µL, 2 µL) Gilson Inc, USA 
Polytron homogenizer PT 2500E Kinematica, Switzerland  
Power Pac 300 gel electrophoresis unit BioRad, Munich 
Power Station 300 gel electrophoresis unit Labnet International, USA  
RH Basic heating plate with magnetic stirrer IKA, Staufen 
Select vortexer Select BioProducts, USA 
SunriseTM microplate reader for ELISA Tecan, Austria 
TBS 88 paraffin embedding system Medite, Burgdorf 
Thermomixer 5436 Eppendorf, Hamburg 
Trans Blot® SD Semi-Dry transfer cell BioRad, Munich 
Varioklav 400 autoclave H+P Labortechnik, 
Oberschleißheim 
WB 6 water bath Preiss-Daimler Group, 
Puschwitz 
X-ray cassette Rego, Augsburg  
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2.4. Antibodies, drugs, enzymes and oligonucleotides 
Primary antibodies 
Monoclonal mouse anti-CFTR, clone CF3 abcam, UK 
Monoclonal mouse anti-CFTR; Antibody 528 CF Foundation, USA 
Monoclonal mouse anti-CFTR; Antibody 570 CF Foundation, USA  
Monoclonal mouse anti-CFTR; Antibody 596 CF Foundation, USA 
Monoclonal mouse anti-CFTR; Antibody 660 CF Foundation, USA  
Monoclonal mouse anti-CFTR; Antibody 769 CF Foundation, USA 
Monoclonal mouse anti-human CFTR; R&D Systems, Wiesbaden 
clone #24-1 
Polyclonal goat anti-CFTR; N-20 Santa Cruz, Heidelberg 
Polyclonal rabbit anti-CFTR; #2269 Cell Signaling, Frankfurt am 
Main 
Polyclonal rabbit anti-CFTR; H-182 Santa Cruz, Heidelberg 
Secondary antibodies 
Biotinylated goat anti-mouse IgM; BA-2020 Vector Laboratories, USA 
Biotinylated goat anti-rabbit IgG; BA-1000 Vector Laboratories, USA 
Biotinylated polyclonal AffiniPure Jackson ImmunoResearch, USA 
goat-anti-mouse IgG 
Biotinylated polyclonal goat anti-mouse IgG, Dako, Hamburg 
#E0433 
Biotinylated rabbit anti-goat IgG, BA-5000 Vector Laboratories, USA  
HRP-conjugated goat anti-rabbit IgG Cell Signaling, Frankfurt am 
Main 
HRP-conjugated polyclonal AffiniPure Jackson ImmunoResearch, USA 
mouse anti-goat IgG 
HRP-conjugated polyclonal goat anti-mouse IgG Dianova, Hamburg 
Alexa Fluor 488-conjugated AffiniPure Jackson ImmunoResearch, USA 
donkey anti-mouse IgG  
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Drugs 
Altrenogest (Regumate®) Serumwerke Bernburg, 
Bernburg 
Azaperon (Stresnil®) Janssen Pharmaceutica, 
Belgium 
Choriongonadotropine (hCG) (Ovogest®) Intervet, Unterschleißheim 
Cloprostenol (Estrumate®) Intervet, Unterschleißheim 
Diatrizoate meglumine and diatrizoate sodium  Bayer Health Care AG, 
solution (Gastrografin®) Leverkusen 
Embutramid, Mebezonium, Tetracain (T61®) Intervet, Unterschleißheim 
Glucose solution 50 % B. Braun, Melsungen 
Ketamine hydrochloride (Ursotamin®) Serumwerke Bernburg, 
Bernburg 
Omeprazol (OMEP®) Hexal AG, Holzkirchen 
Pancreatin (Eurobiol®) Laboratoires Mayoli Spindler, 
France 
PMSG (Intergonan®) Intervet, Unterschleißheim 
Potassium chloride solution 7.5 % B. Braun, Melsungen 
Sodium chloride solution 0.9 % ad us. vet. B. Braun, Melsungen 
Enzymes 
BigDye® Terminator v3.1 Applied Biosystems, 
Weiterstadt 
DNase I, RNase-free (1 U/µL) Thermo Scientific, Schwerte 
FastStart Essential DNA Green Master Roche Diagnostics, Mannheim 
Proteinase K, ready to use Dako, Hamburg 
RevertAid H Minus Reverse Transcriptase Thermo Scientific, Schwerte 
(200 U/µL)   
SuperScript® III Reverse Transcriptase Thermo Scientific, Schwerte  
(200 U/µL) 
Taq DNA Polymerase (5 U/mL) Agrobiogen, Hilgertshausen  
Uracil N-Glycosylase (UNG) (1 U/µL) Thermo Scientific, Schwerte 
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Oligonucleotides 
All oligonucleotides were designed with the PrimerQuest Tool by IDT and were 
purchased from Thermo Scientific, Schwerte. 
 
CFTR3f 5-GAC AGT ACT GCT TAG TGG TCA G-3 
CFTR3r 5-CAG ATC TAG AAT TCT GGT ATG-3 
Neo3f  5-GAG AAC CTG CGT GCA ATC CAT C-3 
Neo2f  5-GAG ATG AGG AAG AGG AGA ACA G-3 
CFTR2f 5-GAT CTG CTA CTT AGT AGT TAC TG-3 
CFTR2r 5-CAA TTC CTC AAG TAC AGA TC-3 
Cg1f  5-AAT GAC ATC ACE GCA GGT CAG A-3 
Cg2f  5-AGA AGA GTA GGG CCT TTG GCA T-3 
Cg1r  5-TGG CTG AAC TGA GCG AAC AAG T-3 
Cg2r  5-ATT CCA CCA CTG CTC CCA TTC A -3 
Cg3r  5-TGG CTC ATC ACA TGC AAA GCA G-3 
Cg4r  5-CCT CCA GTA TGT GTG CCA AGA A-3 
Cg5r  5-AGC ACA TGT GGG TCT TAG AGT ACG-3 
STOPr  5-CCA ATT ATG TCA CAC CAC AG-3 
CFTR7118rv 5-GAG AAG ATG CTG GCC TTT TCC-3 
CFTR5armf 5-TGA GCA GTT TGT CTG GAG CAT-3 
CFTR7160rv 5-TCC AAA GCT CAG CTA GAC ACC-3 
pACT954f 5-CGC TCG TGG TCG ACA ACG-3 
pACT1919r 5-CTG GAT GGC CAC GTA CAT G-3 
FEqf1  5-TGG CAT TTG ATG GTG CCT GGA A-3 
FEqf2  5-TGC CTG GAA GAT AGA CCG CAA T-3 
FEqf3  5-ACG GAA CTG AAC TCA CTG GGA A-3 
FEqr1  5-GCT GCA AGT TTC CTC TTT ACC ACG-3 
FEqr2  5-GTC ATG AGC TGC AAG TTT CCT C-3 
FEqr3  5-TTC CCA GTG AGT TCA GTT CCG T-3 
FEqr4  5-TGG GCT GTG CTC CAA GAA CAA T-3 
CEqf1  5-AGA GTC ACA AGA GAG CCC ATC A-3 
CEqf2  5-ACA TCC CTT CTC TGG GAA ATG GGT-3 
CEqf3  5-AGT GAA CGT GTC TGC TGC CAG TAA-3 
CEqr1  5-ACT TAC TGG CAG CAG ACA CGT T-3 
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CEqr2  5-TGC CTG GAG CTT CTG TGG TAA GAA-3 
CEqr3  5-ACA TCT ACC TGT AGT GCC CAG A-3 
Lars1f  5-CCT GGC AAG CTT GAT TTT G-3 
Lars1ra 5-CTA AAG TCT TGT TTC TTG C-3 
Lars2f  5-AAC CTG AAC AAG TTT GAT GAA G-3 
Lars2r  5-AAG GCA AGT CCA CAG AAG GC-3  
CFgutf1 5-CCG TGA ATG TGG ACG AAGT-3 
CFgutr1 5-TCG AGC TCC TAA TGC CAA AG-3 
CFgutf2 5-GAA GAA GAG GTG CAA GAA ACA AG-3 
CFgutr2 5-CTG GCA ACT AGA AGG CTC AG-3 
CFgutf3 5-TGA AGG AGG AAA CAG AAG AAG AG-3 
CFgutr3 5-CAG ATG GCT GGC AAC TAG AA-3 
CFgutf4 5-TTC TAG TTG CCA GCC ATC TG-3 
CFgutr4 5-TAG GAA AGG ACA GTG GGA GT-3 
CLCA4b1f 5-GAG AGG TAT TCA AGG CCA CTT AG-3 
CLCA4b2f 5-TTC CAC ATG CTA CAG GAA GAA A-3 
CLCA4b3f 5- CAG CTT GGA TCT GGC ATT ACT-3 
CLCA4b1r 5- CTC CTC TGT ACG TCT CCT GTT A-3 
CLCA4b2r 5- GAG GGC CTT AGG AAG AGA GA-3 
CLCA4b3r 5-CAC AGC ACC TTC AGA GTT GA-3 
2.5. Buffers and solutions 
Water deionized in a Millipore device (EASYpure® II, pure aqua, Schnaitsee) and 
termed as aq. bidest. was used as solvent. All buffers and other solutions were 
stored at room temperature if not indicated otherwise. 
Buffers and solutions for PCR and agarose gels 
DNA loading buffer (10 ×) 
10 % glycerol in aq. bidest. 
1 spatula tip of Bromophenol Blue 
Add 0.5 M NaOH until color turns blue. 
Stored aliquoted at 4 °C. 
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dNTP-mix 
2 mM dATP, dCTP, dGTP, dTTP 
Mixed in aq. bidest. 
Stored aliquoted at -20 °C. 
 
TAE buffer (50 ×) 
242 g 2 M Tris 
100 mL 0.5 M EDTA (pH 8.0) 
57 mL glacial acetic acid 
Ad 1000 mL aq. bidest. 
Buffer solution was filtrated and autoclaved for storage. 
Before usage, the buffer solution was diluted to single concentration. 
 
Gene RulerTM 1 kb DNA molecular weight standard 
100 µL Gene RulerTM 1 kb DNA molecular weight standard 
100 µL 6 × loading dye 
400 µL aq. bidest. 
Stored aliquoted at -20 °C. 
 
Sequencing buffer (5 ×) 
17.5 mL 1 M Tris/HCl (pH 9.0) 
125 µL 1 M MgCl2 
Ad 50 mL aq. bidest. 
Stored aliquoted at -20 °C. 
Buffers and solutions for RNA isolation and cDNA synthesis 
10 mM Tris/HCl pH 8.0 
10 mM Tris 
Adjust pH to 8.0 with HCl. 
 
10 mM dNTPs 
10 mM dATP, dCTP, dGTP, dTTP 
Mixed in aq. bidest. 
Stored aliquoted at -20 °C. 
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25 × MOPS 
2 M MOPS 
500 mM NaOAc 
10 mM EDTA 
Mixed in aq. bidest. 
Stored in the dark at 4 °C. 
 
RNA denaturating buffer 
750 µL formamide 
250 µL formaldehyde 
150 µL 25 × MOPS 
116 µL glycerol 86 % 
122 µL bromophenol blue 0.25 % 
122 µL xylene cyanole 0.25 % 
6 µL EtBr 
Stored aliquoted at -80 °C. 
Buffers and solutions for fixation and immunological detection 
Methacarn 
60 % methanol 
30 % chloroform 
10 % acetic acid (glacial) 
Prepared freshly, stored in the dark. 
 
4 % PFA solution 
4 % PFA 
1 × PBS buffer 
Solution was heated to 50 °C in a water bath and was vigorously shaken 
several times. For complete dissolution of PFA, 200 µL of 5 M NaOH 
were added to raise the pH. After cooling down to room temperature, the 
solution was adjusted to pH 7.4 with HCl, filtered and stored at 4 °C.  
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2 % PFA solution 
2 % PFA 
1 × PBS buffer 
Solution was heated to 50 °C on a warming plate and mixed with a 
magnetic stirrer. For complete dissolution of PFA, 200 µL of 5 M NaOH 
were added to raise the pH. After cooling down to room temperature, the 
solution was adjusted to pH 7.4 with HCl, filtered and stored at 4 °C. 
 
30 % sucrose 
300 g sucrose 
Ad 1000 mL aq. bidest. 
After filtration the solution was stored at 4 °C. 
 
Citrate buffer 
10 mM sodium citrate pH 6 
0.05 % Tween 20 
Sodium citrate and aq. bidest. were mixed and pH was adjusted to 6 with 
HCl. Tween 20 was added and the solution was mixed well. 
 
10 × TBS buffer for IHC 
90 g NaCl 
60.5 g Tris 
Ad 1000 mL aq. bidest. 
Adjusted to pH 7.6. 
Concentrated stock solution of buffer was autoclaved and diluted to single 
concentration with aq. bidest. before use. 
 
DAB solution 
One tablet DAB was dissolved in 10 mL aq. bidest. in the dark and was 
shaken several times. 
Aliquots were stored at -20 °C.  
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Buffers and solutions for Western Blots 
Laemmli buffer (5 ×) 
65.5 mL 1 M Tris pH 6.8 
100 mL Glycerol (100 %) 
2 mL 0.5 M EDTA pH 8 
20 g SDS 
0.01 % bromophenol blue 
Ad 200 mL aq. bidest. 
 
PBS buffer (10 ×) 
136 mM NaCl 
8.1 mM Na2HPO4 
2.7 mM KCl 
1.5 mM KH2PO4 
Adjusted to pH 7.4. 
After filtration, buffer solution was autoclaved and diluted to single 
concentration with aq. bidest. before use. 
 
Complete Proteinase inhibitor solution (25 ×) 
One tablet was dissolved in 2 mL aq. bidest. to obtain a 25 × stock 
solution. 
Stored at 4 °C and used within 12 weeks. 
 
Protein extraction buffer (1 × Laemmli) 
2 mL 1 M Tris (pH7.5) 
2 mL Triton X-100 
20 mL 5 × Laemmli buffer 
4 mL 25 × Complete proteinase inhibitor solution 
76 mL aq. bidest.  
III. Animals, materials and methods     35 
Ponceau S solution 
0.2 g Ponceau 
3 mL glacial acetic acid 
Ad 100 mL aq. bidest. 
 
SDS running buffer (10 ×) 
30.3 g Tris 
144 g glycine 
10 g SDS 
Ad 1000 mL aq. bidest. 
Stored at 4 °C. 
Buffer was diluted to single concentration with aq. bidest. before use. 
 
Transfer buffer (10 ×) 
58 g Tris 
29 g glycine 
3.7 g SDS 
Ad 1000 mL aq. bidest. 
Stored at 4 °C. 
 
Transfer buffer (1 ×) 
20 mL 10x Transfer buffer 
140 mL aq. bidest. 
40 mL methanol 
Prepared freshly. 
 
TBS buffer for WB (10 ×) 
80 g NaCl 
30 g Tris 
Ad 1000 mL aq. bidest. 
Adjusted to pH 7.4. 
Concentrated stock buffer was autoclaved.  
III. Animals, materials and methods     36 
TBS-T (0.1 %) (1 ×) 
100 mL 10x TBS 
1 mL Tween-20 
Ad 1000 mL aq. bidest. 
 
TBS-T-BSA 
0.1 % TBS-T 
5 % BSA 
 
TBS-T-w/v nonfat dry milk 
0.1 % TBS-T 
5 % w/v nonfat dry milk 
 
Elution buffer 
62.5 mM Tris/HCl pH 6.7 
2 % SDS 
100 mM 2-mercaptoethanol 
 
2.6. Kits 
Direct-zolTM RNA MiniPrep Kit Zymo Research, Freiburg 
Double Pure Kombi Kit Bio&SELL, Nürnberg 
Easy-DNATM Kit Invitrogen, Karlsruhe 
Isohelix DDK DNA Isolation Kit Cell Projects Limited, UK 
NexttecTM Genomic DNA Isolation Kit Nexttec GmbH, Leverkusen 
Vectastain ABC Komplex Vector Laboratories, UK 
2.7. Other reagents 
0.1 M DTT for cDNA synthesis Thermo Scientific, Schwerte 
10 × PCR buffer Agrobiogen, Hilgertshausen 
10 × DNase reaction buffer with MgCl2 Thermo Scientific, Schwerte 
5 × First-Strand buffer for cDNA synthesis Thermo Scientific, Schwerte  
5 × RevertAid reaction buffer Thermo Scientific, Schwerte 
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6 × DNA loading dye Thermo Scientific, Schwerte 
Bovine serum albumin (BSA) fraction V Roth, Karlsruhe 
dNTPs (dATP, dCTP, dGTP, dTTP) Thermo Scientific, Schwerte 
Gelatin from cold water fish skin Sigma, Steinheim 
Gene RulerTM (1 kb DNA ladder) Thermo Scientific, Schwerte 
DNA molecular weight standard 
Oligo (dT) primer Thermo Scientific, Schwerte 
PageRulerTM prestained protein ladder Thermo Scientific, Schwerte 
Random primer hexamers (600 μg/µL) Thermo Scientific, Schwerte 
RiboLock RNase inhibitor (40 U/µL) Thermo Scientific, Schwerte 
Serum (goat, rabbit, pig) MP Biomedicals, France 
Unstained protein molecular weight marker Thermo Scientific, Schwerte 
2.8. Software 
BioEdit Sequence Alignment Editor 
FinchTV Version 1.3.1, Geospiza Inc. 
GraphPad PRISM version 5.02 
LightCycler® 96 Application Software 1.1.0.1320 
ImageJ 1.49m, National Institutes of Health, USA 
AxioVision 4.0, Carl Zeiss Microscopy 
3. Methods 
3.1. Production of CFTR-/-, CFTR+/- and WT piglets by breeding 
Male CFTR+/- piglets generated by SCNT were grown to maturity and mated to 
female WT sows. Female and male CFTR+/- offspring were kept as a breeding 
herd and selectively mated to each other to produce litters with WT, CFTR+/- and 
CFTR-/- piglets. Female CFTR+/- gilts were either estrus-synchronized by oral 
administration of altrenogest (5 mL/animal) over a period of at least 15 days or 
mated when estrus appeared naturally. Pregnancy was controlled in regular 
intervals of about 3 weeks via medical ultrasonic and birth routinely induced by 
i.m. injection of 2 mL of cloprostenol on day 113 of the pregnancy.  
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Sows farrowed usually between 24 and 36 hours after the cloprostenol injection 
and were surveyed during the birth process.  
3.2. Generation of gut-modified CFTR-/- founder animals 
Gut-modified CFTR-/- piglets were generated by additive gene transfer followed 
by SCNT and ET. For this purpose, an expression vector constructed by N. 
Klymiuk, Chair for Molecular Animal Breeding and Biotechnology, LMU 
Munich was transfected into the primary kidney cells of CFTR-/- piglets. The 
DNA construct consisted of a 1.2 kb fragment of the porcine Fatty-acid Binding 
protein 2 (FABP2) promoter, a 215 bp long part of the porcine β-hemoglobin 
(HBB) gene, the 4.8 kb coding region of the porcine CFTR followed by the 277 bp 
long polyadenylation signal of the bovine Growth Hormone (bGH) gene and a 
puromycin® resistance cassette. 
Stable transfected pooled cell clones were recognized by positive antibiotic 
selection, taken as donors for SCNT using in vitro matured oocytes and cloned 
embryos laparoscopically transferred to gilts (Kurome, Kessler et al. 2015). An 
overview of the routine workflow is given in Figure 1. Gilts were pre-
synchronized by oral administration of altrenogest for at least 15 days, i.m. 
injection of 750 IU of PMSG 36 hours after the last altrenogest administration and 
i.m. injection of 750 IU of hCG 3 days after PMSG injection. ET was performed 
about 36 hours after hCG injection. Pregnancy was confirmed by ultrasonic 
examinations in regular intervals and birth routinely induced by 2 mL i.m. 
injection of cloprostenol on day 114 of the pregnancy. Piglets with a promising 
phenotype could be recloned by explantation of the euthanized animal’s kidney 
and establishment of cell cultures of cells from this kidney that could be used for 
NT and SCNT.  
Cell culture experiments were executed by A. Wünsch, Chair for Molecular 
Animal Breeding and Biotechnology, LMU Munich; SCNT and ET were 
performed by M. Kurome, B. Kessler, V. Zakhartchenko and T. Güngör, Chair for 
Molecular Animal Breeding and Biotechnology, LMU Munich.  
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Figure 1: Generation of gut-modified CFTR-/- piglets. CFTR-/- kidney cells 
transfected with the transgenic DNA construct are used for somatic cell nuclear 
transfer and embryo transfer. 
3.3. Management of neonatal gut-modified CFTR-/- piglets 
After delivery, gut-modified CFTR-/- piglets were kept under 24 h surveillance and 
supportive treatments were undertaken to increase the probability of removing 
meconium ileus. The piglets were weighed immediately after birth, received ear 
marks for identification and their tails were docked to serve as material for 
genotyping. All piglets were treated with repeated gastrografin enemas every 8 h 
to facilitate deposit of meconium, received omeprazol as gastric protection every 
12 h and pancreatic enzymes were substituted every 24 h using pancreatin. For 
circulation support, prewarmed 0.9 % NaCl / 5 % glucose / 0.2 % KCl was given 
every 4 h via stomach tube. If the piglets were not able to drink themselves, the 
sow was milked and the animals were fed at least 20 mL of milk via stomach tube 
every two hours to ensure colostrum intake. Every 2 h, the general condition of 
the piglets was checked with special attention to motility, defecation and 
abdominal pressure. 
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Piglets were treated according to this protocol: 
Table 1: Treatment protocol for gut-modified CFTR-/- piglets. 
Birth  Earmarks and tail docking 
 Weighing 
 Ensuring colostrum intake 
 1 mL gastrografin enema 
Birth + 4 h  10 crushed grains of Eurobiol® and half the content of one 
capsule of OMEP® are mixed with 20 mL 0.9 % NaCl / 
5 % glucose / 0.2 % KCl and fed via stomach tube 
Birth + 8 h  20 mL 0.9 % NaCl / 5 % glucose / 0.2 % KCl via stomach 
tube 
 1 mL gastrografin enema 
Birth + 12 h  20 mL 0.9 % NaCl / 5 % glucose / 0.2 % KCl via stomach 
tube 
Birth + 16 h  10 crushed grains of Eurobiol® in 20 mL 0.9 % NaC l/ 5 % 
glucose / 0.2 % KCl via stomach tube 
 1 mL gastrografin enema 
Birth + 20 h  20 mL 0.9 % NaCl / 5 % glucose / 0.2 % KCl via stomach 
tube 
Birth + 24 h  20 mL 0.9 % NaCl / 5 % glucose / 0.2 % KCl via stomach 
tube 
 1 mL gastrografin enema 
 Weight control 
If the general condition of a piglet started to deteriorate considerably without any 
signs of meconium removal and the piglet showed a bloated, pear-shaped, hard 
abdomen, the piglet was anaesthetized i.m. with ketamine hydrochloride 
(2 mL/10 kg BW) and azaperone (0.5 mL/kg BW) followed by euthanization via 
i.c. injection of Embutramid, Mebezonium, Tetracain (1 mL/10 kg BW). 
3.4. Necropsy of CF piglets 
In order to compare intestinal phenotypes and expression patterns, samples were 
taken from gut-modified CFTR-/-, WT, CFTR+/- and CFTR-/- piglets. After 
euthanization, a series of pictures was taken to document the severity of the 
intestinal phenotype, including pictures of the opened abdomen, the intestinal 
convolute in whole and the intestine laid out in full length. A range of organ 
samples were taken for expression analysis at protein and RNA level. Tissue 
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samples were collected from the lung, trachea, heart, liver, kidney, pancreas and 
from different parts of the intestine (duodenum, proximal and distal jejunum, 
ileum and colon). 
 
 
Figure 2: Sampling of the intestine. The different parts of the intestine used for 
sample collection are defined as follows: The duodenum reaches from pylorus to 
the plica duodenocolica; samples from the proximal and distal jejunum were 
collected within the first and the last third, respectively; the ileum is defined by 
the length of the plica ileocaecalis and colon samples were taken from the gyri 
centripetales of the colon ascendens. 
For RNA and protein isolation purposes, organ samples were cut into small pieces 
and quick-frozen on dry ice as fast as possible to prevent degradation. Samples 
were wrapped in tin foil and stored at -80 °C until further examination. After the 
sampling of each organ, the surgical instruments were disinfected with 70 % 
ethanol to prevent contamination. 
For immunological detection of CFTR on cryo-sections, tissue was frozen in two 
different ways. In the first freezing method, organs were cut into thin slices with a 
sharp scalpel knife, embedded in cryo-molds containing optimal cutting 
temperature (OCT) compound and frozen quickly on dry ice. The second freezing 
method consisted of a fixation step of the tissue block in 2 % PFA at RT for 1 h, 
followed by incubation in ice-cold 30 % sucrose overnight. The next day, tissue 
slides were embedded in OCT in cryo-molds and quick-frozen in a 
III. Animals, materials and methods     42 
70 % ethanol/dry ice bath. Until further processing, cryo-molds were stored at -
80 °C. 
For immunological detection of CFTR in paraffin sections, 1 cm × 1 cm × 1 cm 
blocks were cut out of organs with a sharp scalpel knife and put in falcons 
containing either methacarn solution or Roti-Histofix 4 % for fixation. Falcons 
containing methacarn solution had to be stored on ice protected from light. About 
6 h after collecting the samples, the tissue blocks were cut into thin slices with a 
sharp microtome knife and the slices were put into embedding cassettes for further 
fixation in the respective fixation solution. After about 24 h, cassettes in 
methacarn solution were transferred directly to 70 % ethanol while cassettes in 
4 % PFA were first watered with tap water for 30 min, then watered with aq. dest. 
for 30 min and finally transferred to 70 % ethanol. Cassettes were stored in 70 % 
ethanol until embedding in paraffin. 
3.5. Preparation of the airways explanted from WT and CFTR-/- piglets 
for experiments on mucociliary transport 
Before starting, the transport solution Perfadex® was prepared by adjusting the 
pH to 7.4 with 1 M Tris solution. Piglets were anaesthetized i.m. with ketamine 
hydrochloride (2 mL/10 kg BW) and azaperone (0.5 mL/kg BW), followed by 
euthanization via i.c. injection of Embutramid, Mebezonium, Tetracain 
(1 mL/10 kg BW) (Figure 3 (1)). The thorax was opened (Figure 3 (2)) and, 
starting from the larynx, the trachea, the lungs and the heart were explanted 
(Figure 3 (3)). The heart and the mediastinum containing the esophagus and big 
blood vessels were removed, while repeatedly bathing the airways in Perfadex® 
solution (Figure 3 (4)). Pulmonary tissue was carefully pulled away with forceps 
in a petri dish filled with Perfadex® (Figure 3 (5)) until only the bronchial system 
was left (Figure 3 (6 and 7)). Airways were sent in 50 mL falcons containing 
Perfadex® solution at 4 °C to the Mucin Biology Group, Gothenburg for further 
analysis (Figure 3 (8)).  
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Figure 3: Preparation of the airways. 
All experiments on WT and CF KO tracheas were performed by Anna Ermund 
from the Mucin Biology Group at the University of Gothenburg. 
For video microscopy imaging of living tissue, tracheas were mounted in a petri 
dish containing Krebs buffer aerated with 95 % O2 /5 % CO2 (10 mM glucose, 
5.1 mM Na-glutamate, 5.7 mM Na-pyruvate, 116 mM NaCl, 1.3 mM CaCl2, 
3.6 mM KCl, 1.4 mM KH2PO4, 23 mM NaHCO3, and 1.2 mM MgSO4, pH 7.4). 
Mucus was stained with Alcian blue 8GX. Time lapses were acquired on a Nikon 
stereo microscope and a Nikon color camera and strand velocity was calculated 
using the program NIS elements. 
For Muc5b and Muc5ac antibody staining, WT and CF KO airways were fixed in 
4 % PFA, paraffin embedded, sectioned and then used for immunofluorescence 
microscopy. The rabbit anti-Muc5b antibody was a kind gift from Dr. Mehmet 
Kesimer, UNC Chapel Hill and the Muc5ac antibody was the mouse monoclonal 
antibody clone 45M1 purchased from Sigma Aldrich. Secondary antibodies were 
donkey anti-rabbit Alexa Fluor 488 and donkey anti-mouse Alexa Fluor 555 
(Thermo Scientific, Schwerte). Images were acquired with an upright LSM 700 
Axio Examiner 2.1 confocal imaging system. 
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For scanning electron microscopy (SEM), WT and CF KO airways were fixed in 
Karnovsky fixative (2 % paraformaldehyde and 2.5 % glutaraldehyde in 0.05 M 
sodium cacodylate buffer, pH 7.2) for 24 h. Specimens for SEM were dehydrated 
in ethanol followed by immersion in hexamethyldisilazane and evaporation in a 
fume hood. The dried specimens were mounted on stubs and sputter-coated with 
palladium before examination in a Zeiss 982 Gemini field emission scanning 
electron microscope. 
3.6. Analysis at the genomic level 
As the state of health of CFTR-/- piglets started to deteriorate after about 12 h post-
partum because of failure to remove meconium, a very fast genotyping protocol 
had to be established to differentiate between genotypes, including rapid DNA 
isolation and a time-saving genotyping Polymerase Chain Reaction (PCR). 
3.6.1. Genotyping of piglets 
Three DNA isolation procedures using different starting materials were compared 
in order to establish the fastest and most reliable protocol. 
Isolation of genomic DNA from tails 
Genomic DNA from freshly docked tails of newborn piglets was isolated using 
the nexttecTM Genomic DNA Isolation Kit from Tissue and Cells (nexttec GmbH, 
Leverkusen) according to the manufacturer’s instructions. A very small amount of 
tissue (about 3 small pieces with a diameter < 1 mm) was incubated in lysis buffer 
in a 2 mL Eppendorf tube using a thermomixer with 1,200 rpm at 60 °C for 
30 min. 3 µL DTT were added to each sample to ensure proper lysis and to 
increase the DNA yield. The sample was vortexed vigorously several times to 
accelerate the lysis of tissue pieces. After 30 min, the lysate was purified on an 
equilibrated cleaning column and the eluate containing the purified DNA was 
immediately used for PCR.  
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Isolation of genomic DNA from buccal swabs 
The Isohelix DDK DNA Isolation Kit (Cell Projects Limited, UK) was employed 
for the isolation of genomic DNA from buccal swabs. For this purpose, buccal 
cells were collected by scratching the oral mucosa of newborn piglets with 
Isohelix buccal swabs. Afterwards, the DNA was isolated according to the 
manufacturer’s instructions taking all optional steps to increase DNA yield and 
improve purity. The volume for resuspension of the DNA pellet was decreased to 
an amount of 55 µL TE solution to achieve a higher DNA concentration. The 
DNA concentration was measured at 260 nm with the GeneQuant Pro photometer 
and the purity was checked by measuring 260 nm/ 280 nm and 260 nm/ 230 nm 
ratios. The DNA sample was then immediately used as a template for PCR. 
Isolation of genomic DNA from blood samples 
For the isolation of genomic DNA from blood samples, the Easy-DNATM Kit, 
protocol #2 – 30 min DNA extraction from blood samples (InvitrogenTM, 
Karlsruhe) was used. 1 mL of venous blood was taken from the V. cava with 
EDTA monovettes and the DNA was isolated according to the manufacturer’s 
instructions. The DNA pellet was resuspended in 105 µL T-buffer to increase 
DNA yield and to stabilize the DNA. After isolating the DNA, the concentration 
and purity were measured using the GeneQuant Pro spectrophotometer, the DNA 
was diluted to a concentration of 100 ng/µL and then used as a template for PCR. 
PCR 
Two different sets of primers detecting the WT and the transgenic sequence of the 
CFTR locus were tested for genotyping of CF piglets. To identify gut-modified 
CFTR-/- piglets, an additional PCR detecting specific parts of the expression 
vector was established. To identify optimal conditions, different annealing 
temperatures were tested via temperature gradient PCR and different primer 
concentrations were checked. The PCR components were mixed on ice to a final 
volume of 25 µL in 0.2 mL reaction tubes. Previously isolated genomic DNA 
from WT, CFTR+/- and CFTR-/- piglets served as control and aq. dest. was used as 
a non-template control. Details for master mix ingredients and PCR conditions are 
listed in Table 2 and Table 3 below. 
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Table 2: Master mix composition for genotyping PCRs. 
10 × PCR buffer 2.5 µL 
MgCl2 (15 mM) 2.5 µL 
dNTPs (2 mM) 2.5 µL 
Primer f (10 µM) Xx µL 
Primer r (10 µM) Xx µL 
Taq Polymerase (5 U/µL) 0.2 µL 
aq. dest. Ad 24 µL 
DNA template 1 µL 
 
Table 3: Cycler protocol for genotyping PCRs. 
Denaturation 95 °C 5 min  
Denaturation 95 °C 30 s 
35 × Annealing Xx °C 30 s 
Elongation 72 °C 1 min 
Final elongation 72 °C 10 min  
Termination 4 °C 15 min  
Agarose gel electrophoresis 
To prove the presence of amplified DNA, agarose gel electrophoresis was 
employed. For this purpose, a 1 % agarose gel was prepared by heating 1 × TAE 
buffer with 1 g/100 mL Universal Agarose in the microwave until the agarose had 
completely dissolved. After cooling down to about 55 °C, ethidium bromide was 
added to the mixture in a concentration of 0.5 µg/mL and the gel was poured into 
an electrophoresis chamber (OWL Inc., USA) for polymerization. After 
termination of the PCR, 2.5 µL 10 × DNA loading buffer were added to each PCR 
sample and the chamber was filled with 1 × TAE buffer as running buffer. 6 µL of 
Gene RulerTM 1 kb DNA molecular weight standard for the determination of the 
fragment size as well as the samples were pipetted into individual gel slots. By 
application of an electric field with a voltage of about 130 V, the DNA samples 
were separated according to their size and were visualized under UV light 
afterwards. The size of the bands could be estimated on the basis of the DNA 
marker. 
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3.6.2. Sequencing of PCR products 
For verification of the correct amplification of the DNA, bands of the correct size 
were cut out of the gel, the DNA was eluted and then sequenced. 
DNA elution 
For sequencing purposes, amplified DNA as well as a Gene RulerTM 1 kb DNA 
molecular weight standard were loaded onto a 1 % UltraPureTM Agarose/ 1 × TAE 
buffer gel. Under UV light, bands of the correct size were cut out of the gel. DNA 
was eluted from the gel according to “protocol 1: isolation of DNA from agarose 
gels” from the Bio&Sell Double Pure Kombi Kit. All steps were performed 
according to the manufacturer’s instructions. For final DNA elution (step 8), 
30 µL of elution buffer, preheated to 50 °C, were used to increase the DNA yield. 
To confirm the successful elution, 
2 µL DNA elute 
2 µL 10 × DNA loading buffer 
15 µL aq. bidest. 
were mixed together and loaded on a 1 % agarose gel. A Gene RulerTM 1 kb DNA 
molecular weight standard was used as marker. 
Sequencing PCR 
The DNA base sequences of the amplified DNA were determined via the Sanger-
DNA sequencing approach. For this purpose, PCR components were mixed on ice 
to a final volume of 10 µL in 0.2 mL reaction tubes (see Table 4). Each sample 
was sequenced twice, once with a forward, and once with a reverse primer. The 
same primers used for genotyping were employed for the sequencing reaction.  
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Table 4: Master mix composition for sequencing PCRs. 
5 × Sequencing buffer 4 µL 
BigDye 1 µL 
Primer (10 µM) 1 µL 
aq. dest. 2 µL 
DNA template 2 µL 
 
Table 5: Cycler protocol for sequencing PCRs. 
Denaturation 95 °C 1 min  
Denaturation 95 °C 5 s 
40 × Annealing 50 °C 10 s 
Elongation 60 °C 4 min 
Termination 4 °C 15 min  
Ethanol Precipitation 
After terminating the PCR run, an ethanol precipitation was performed for 
purification of the cycle-sequenced products. 2.5 µL of 125 mM EDTA and 30 µL 
of 100 % EtOH, precooled to -20 °C, were added to the amplified PCR mix and 
the mixture was transferred to a fresh 1.5 mL tube. Subsequently, the samples 
were incubated on ice for 15 min. After centrifugation at 13,000 rpm for 30 min at 
4 °C, the supernatant was removed with a pipette and the pellet was washed in 
50 µL of 70 % EtOH. Afterwards the samples were centrifuged at 13,000 rpm for 
2.5 min, the liquid supernatant was removed with a pipette and the pellet was air-
dried for 6 min. The pellet was resuspended in 30 µL aq. dest. and transferred to a 
sequencing plate. The analysis of the fluorescently labeled DNA fragments was 
carried out at the Genome Analysis Center, Helmholtzzentrum Munich, with the 
automated capillary electrophoresis system ABI 3730 48-capillary DNA 
Analyzer. 
Nucleotide sequences were evaluated bioinformatically with FinchTV Version 
1.3.1, Geospiza Inc. and the BioEdit Sequence Alignment Editor. 
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3.7. Expression analysis at the RNA level 
For expression analysis at the RNA level, RNA had to be isolated from tissue 
samples and reverse transcribed into cDNA. An absolute quantification of CFTR 
and gut-modified CFTR expression was performed via quantitative PCR (qPCR) 
in comparison to the ubiquitously expressed housekeeping gene TBP2. An 
additional qPCR experiment was established for FABP2, as the FABP2-promoter 
served as intestine-specific promoter for the gut-modified CFTR construct. 
3.7.1. RNA isolation 
Two different methods for the isolation of tRNA from tissue material were 
compared – the time-consuming acid guanidinium thiocyanate-phenol-chloroform 
extraction with TRIzol® and the RNA isolation via Direct-zol™ RNA MiniPrep 
Kit. 
RNA isolation with TRIzol® 
Tissue samples stored at -80 °C were put into liquid nitrogen and ground 
thoroughly using a pestle and mortar standing in liquid nitrogen. All working 
steps were performed under a hood in a seperate room where no DNA isolation 
was performed to avoid possible DNA contamination. A maximal amount of 
100 mg of tissue powder was transferred with a microspoon to a 2 mL tube filled 
with 1 mL TRIzol® and homogenized immediately for 10 s at 30,000 rpm with 
the Polytron PT 2500 E rotor stator. Between different samples, the rotor was 
cleaned with aq. dest., 0.2 M NaOH and aq. dest. again to avoid carry-over. After 
an incubation step of 10 min at RT, the samples were centrifuged at 12,000 rcf for 
10 min at 4 °C and the supernatant was transferred to new 1.5 mL tubes. 200 µL 
of chloroform were added to each sample, which were shaken vigorously for 
about 15 s and incubated at RT for 3 min. Following centrifugation at 12,000 rcf 
for 15 min at 4 °C, the mixture separated into the lower phenol/chloroform phase, 
an interphase and the upper aqueous phase containing the RNA. The upper phase 
was transferred carefully with a pipette to a new 1.5 mL tube without disturbing 
the interphase. For RNA precipitation, the aqueous phase was mixed with 500 µL 
of isopropyl alcohol and the samples were incubated for 10 min at RT. After 
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centrifugation at 12,000 rcf for 10 min at 4 °C, the precipitated RNA formed a 
pellet at the bottom of the tube and the supernatant could be removed. The pellet 
was washed with 1 mL of 75 % ethanol, vortexed vigorously and subsequently 
centrifuged at 7,500 rcf for 5 min at 4 °C. The supernatant was removed 
completely and the pellet was left to air-dry at RT for 6 min. The RNA pellet was 
resuspended in 10 mM Tris, pH 8; the volume was chosen according to the size of 
the pellet, and incubated for 10 min at 60 °C. 
The RNA concentration was determined by measuring the absorbance at a 
wavelength of 260 nm and 280 nm with a spectrophotometer. The 260 nm/ 
280 nm and 260 nm/ 230 nm ratios were used to assess the purity of the RNA. If 
the ratio was lower than 1.9 and 2.0, respectively, this could be due to a 
contamination of the RNA with chemicals with stronger absorbance, like TRIzol® 
or protein. 
If required, the overall quality of the isolated RNA was assessed by gel 
electrophoresis on a denaturating 1 % agarose gel. The gel was prepared by 
heating 1.5 g Universal agarose with 135 mL aq. dest. in the microwave until the 
agarose was completely dissolved. Before the gel was poured into a gel 
electrophoresis chamber in the hood, 6 mL 25 × MOPS and 7.5 mL formaldehyde 
were added to the mixture. 1 × MOPS buffer was used as running buffer. The 
RNA samples were prepared as follows: 
10 µL aq. dest. 
5 µL Denaturating Buffer 
2 µL RNA (500 ng/µL) 
Accordingly, a Gene RulerTM 1 kb DNA molecular weight standard was prepared: 
4 µL aq. dest. 
5 µL Denaturating Buffer 
6 µL Gene RulerTM 1 kb DNA molecular weight standard 
The samples were then incubated at 55 °C in a thermomixer for 15 min to 
denature the secondary structures and finally cooled on ice for 2 min. Samples 
were loaded on the gel and the integrity of the RNA was determined by observing 
the visibility of intensive 18S and 28S bands.  
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RNA isolation with the Direct-zol™ RNA MiniPrep Kit 
Tissue samples were prepared as mentioned above, the tissue was homogenized in 
TRIzol® and the supernatant was transferred to a new tube after centrifugation to 
remove any particulate debris. Afterwards, all steps of part II (RNA purification) 
were executed according to the manufacturer’s instructions. RNA concentration 
and integrity were determined as mentioned above. 
DNase digestion 
To remove a possible contamination with genomic DNA, RNA samples were 
treated with DNase I, RNase-free, an endonuclease that digests single- and 
doublestranded DNA. For this purpose, 
2 µL  10 × reaction buffer with MgCl2 
2.5 µL  DNase I, RNase-free 
10.5 µL aq. dest. 
5 µL  RNA (500 ng/µL) 
were mixed together and the samples were incubated at 37 °C. DNase was 
inactivated by heating the mixture to 65 °C for 10 min after addition of 2 µL 
50 mM EDTA. 
3.7.2. cDNA synthesis 
8 µL of the DNase digest, equivalent to 1000 ng RNA, were applied for cDNA 
synthesis. Two different reverse transcriptase enzymes were tested in order to 
obtain the optimal results. The integrity of the obtained cDNA was confirmed by 
amplification of the ubiquitously expressed housekeeping gene ACTB. To check 
for a possible contamination with gDNA, the DNase digest was loaded on the gel 
in addition to the cDNA samples. 
cDNA synthesis with RevertAid H Minus Reverse Transcriptase  
All steps including all optional procedures were executed according to the 
manufacturer’s instructions. To ensure an as complete as possible cDNA 
synthesis, 1 µL of Oligo (dT) and 1 µL of Random Primer Hexamers were used as 
primers. The obtained cDNA was stored at -20 °C until further processing. 
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cDNA synthesis with SuperScriptTM III Reverse Transcriptase 
First strand cDNA synthesis with SuperScriptTM III Reverse Transcriptase was 
executed according to the manufacturer’s instructions. Oligo (dT) was used as 
primer. The obtained cDNA was stored at -20 °C until further processing. 
3.7.3. qPCR 
The aim of qPCR is to determine the amount of an expressed gene in a tissue 
sample by measuring the number of copies of an mRNA transcript in relation to 
the inserted amount of RNA. The amplification of the selected reverse-transcribed 
cDNA can be monitored in real-time by application of a fluorescent dye like 
SYBR Green that intercalates into double-stranded DNA and thereby causes the 
fluorescence to rise with increased concentration of the amplified product. 
The amount of expression of four different genes was determined in the collected 
tissue samples of WT, CFTR-/- and gut-modified CFTR-/- piglets. The expression 
of gut-modified CFTR was measured by amplification of a specific sequence of 
the expression vector spanning the different domains of the vector. The expression 
level of CFTR could be determined by amplification of a region lying within the 
coding sequence of CFTR, thereby detecting both endogenous and transgenic 
CFTR. As the promoter of FABP2 served as intestine-specific promoter for the 
gut-modified expression vector, another qPCR was set up for the determination of 
FABP2. To enable the comparison between different animals, a part of TBP2, a 
housekeeping gene coding for the transcription factor TATA-box binding 
protein 2, was amplified. 
Primers for the different sets of qPCR were tested first in an endpoint PCR run. 
cDNA from intestinal WT and gut-modified CFTR-/- piglets tissue, respectively, 
served as a template. Promising primer pairs were then tested for their suitability 
in qPCR. For this purpose, the following four serial 1:4 dilutions were prepared 
from cDNA and served as template in duplicates: 
1:4  10 µL cDNA  + 30 µL aq. bidest. 
1:16  10 µL 1:4 dilution + 30 µL aq. bidest. 
1:64  10 µL 1:16 dilution + 30 µL aq. bidest. 
1:256  10 µL 1:64 dilution + 30 µL aq. bidest. 
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Different primer concentrations and annealing temperatures were tested to achieve 
optimal results. PCR components were mixed on ice to a final volume of 10 µL in 
a LightCycler® 480 Multiwell Plate 96. To eliminate a carry-over DNA 
contamination from previous runs, Uracil N-Glycosylase (UNG) was included in 
the master mix. The PCR reaction batch and conditions are described in Table 6 
and Table 7. A melting curve analysis was performed following the two-step 
amplification process to assess that one single, specific product was amplified. 
Table 6: Master mix composition for qPCRs. 
FastStart Essential DNA Green Master 6.25 µL 
UNG 0.075 µL 
Primer f (10 µM) Xx µL 
Primer r (10 µM) Xx µL 
aq. bidest. Ad 10 µL 
Template (cDNA) 2.5 µL 
 
Table 7: Cycler protocol for qPCRs. 
UNG activation 50 °C 2 min  
Denaturation 95 °C 10 min 
Denaturation 95 °C 10 s 
45 × 
Annealing Xx °C Xx s 
Melting 95 °C 10 s  
Cooling 37 °C 30 s 
 
To enable a comparison between the different runs and thus establish the optimal 
conditions, standard curves were constructed and analyzed according to Bustin 
(2004). If the linear regression analysis showed a high coefficient of 
determination (R2 > 0.98) and the slope of the standard curve was approximately 
3.32 (equivalent to an amplification efficiency of 100 %), these conditions were 
used for the detection of the corresponding genes. 
Four serial four-fold dilutions of the cDNA of all organ samples of an individual 
served as template performed in duplicates. A non-template control (NTC) served 
as a negative control. Standard curves were established for each tissue and the 
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expression of the selected genes was quantified based on the amplification 
efficiency and Ct values. 
To verify the correct amplification, qPCR products were sequenced via the Sanger 
approach following the same protocol as mentioned under 3.6.2 “Sequencing of 
PCR products” above. 
3.8. Expression analysis at the protein level 
The presence of the CFTR protein should be demonstrated in a set of selected 
tissue samples (see 3.4). Immunohistochemical (IHC) and immunofluorescent (IF) 
staining was employed both for the identification and localization of CFTR in 
tissue sections, whereas western blot (WB) analysis was used for the detection of 
CFTR in protein lysates extracted from snap-frozen tissue. Tissue from WT and 
CFTR-/- piglets, respectively, served as positive and negative controls. 
3.8.1. Immunohistochemical and immunofluorescent detection of CFTR 
The aim of this study was to establish an immunological assay for the reliable and 
specific detection of CFTR in porcine tissue sections. A range of antibodies for 
the detection of porcine CFTR in paraffin-embedded or cryo-sections are 
commercially available. However, evidence for the specificity was limited by the 
unavailability of a real negative control. Therefore, the usage of these antibodies 
for specific detection of porcine CFTR was evaluated with WT lung and intestinal 
tissue as a positive control and tissue of the well-characterized CFTR-/- piglets, 
that are known not to express any CFTR, as a real negative control. 
Processing of fixated tissue material 
Formalin- and methacarn-fixated tissue was routinely processed in a carousel 
tissue processor (Autotechnikon Histomaster 2050/Dl), as described in Table 8.  
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Table 8: Tissue processing for paraffin histology. 
Ethanol 70 % 30 min 
Ethanol 70 % 2 × 1.5 h 
Ethanol 100 % 2 × 1.5 h 
Xylene 2 × 30 min 
Xylene 1.5 h 
Paraffin at 60 °C 2 h 
Paraffin 3 h 
 
Following paraffin embedding with the TBS 88 Paraffin Embedding System, 
sections of about 4 µm were cut with a HM 315 microtome, mounted on 3-
aminopropyltriethoxysilane-treated glass slides and stored at 37 °C until 
immunohistochemical staining. 
Frozen tissue blocks were transferred to a cryotome cryostat (CryoStar NX70) 
holding a temperature of -20 °C. After equilibration of the block temperature to 
the cryotome temperature, sections of about 8 µm were cut and mounted on 3-
aminopropyltriethoxysilane-treated glass slides. Sections were dried overnight at 
room temperature and stored at -80 °C. 
 
Immunohistochemical staining 
The avidin-biotin-complex technique with 3.3’ Diaminobenzidine tetra-
hydrochloride (DAB) as chromogen was used for the detection of CFTR in lung 
and intestine sections. 
Paraffin sections were deparaffinized and rehydrated through a descending 
alcohol row according to Table 9. 
Table 9: Deparaffinization and rehydration of paraffin sections. 
Deparaffinization Xylene 2 × 20 min 
Rehydration Ethanol 100 % 2 × 5 min 
Ethanol 96 % 2 × 5 min 
Ethanol 70 % 5 min 
Washing aq. dest. 2 × 1 min 
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Sections from formalin-fixated tissue had to be pre-treated with antigen retrieval 
agents to break the protein cross-links formed by formalin fixation and thereby 
restoring hidden antigenic sites. In general, at least one heat-induced epitope 
retrieval (HIER) technique, in this case heating by microwave, and the proteinase-
induced epitope retrieval (PIER) with proteinase K were evaluated. For selected 
antibodies, three different HIER methods were tested. Dilutions of H2O2, serum 
and antibodies were prepared with TBS buffer. All steps were performed at RT if 
not indicated otherwise. An overview of the workflow of the standard IHC 
protocol with HIER is given in Table 10. 
Table 10: Standard IHC protocol with HIER. 
 Procedure Agent Conditions 
STEP 1 HIER 10 mM Citrate 
buffer pH 6 +  
0.05 % Tween 
800 W until boiling, 15 
min 320 W in microwave 
Cooling 30 min 
10 mM Citrate 
buffer pH 6 +  
0.05 % Tween 
45 min at 800 W in 
pressure cooker in 
microwave 
Cooling 20 min 
DAKO target 
retrieval solution 
20 min at 97 °C in water 
bath 
Cooling 20 min 
STEP 2 Washing TBS buffer 10 min 
STEP 3 Blocking of 
endogenous 
peroxidase activity 
1 % H2O2 15 min 
STEP 4 Washing TBS buffer 10 min 
STEP 5 Serum blocking 5 % serum 1 h at RT 
STEP 6 Primary antibody  4 °C overnight 
STEP 7 Washing TBS buffer 10 min 
STEP 8 Secondary 
antibody 
 1 h at RT 
STEP 9 Washing TBS buffer 10 min 
STEP 10 Detection ABC complex 30 min 
STEP 11 Washing TBS buffer 10 min 
STEP 12 Substrate DAB  
STEP 13 Rinsing Floating tap water 5 min 
STEP 14 Counterstaining Mayer’s Hemalum 30 s 
STEP 15 Rinsing Floating tap water 5 min 
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In paraffin sections that were treated with proteinase K, endogenous peroxidase 
activity was first blocked with 1 % H2O2 for 15 min, followed by a 10 min 
washing step with TBS buffer. Next, sections were incubated with proteinase K as 
antigen retrieval and subsequently all steps from the standard protocol, beginning 
with STEP 4, were executed. 
For sections from methacarn-fixated tissue that did not need any antigen retrieval, 
the standard protocol was used from STEP 2 onwards. 
Cryo-sections were treated in two different ways. In the first protocol (cryo 
method 1), tissue frozen in OCT compound on dry ice was used, while in the 
second protocol (cryo method 2), tissue incubated in 2 % PFA for 1 h at RT, 
subsequently incubated in ice-cold 30 % sucrose overnight and frozen in OCT 
compound in an ethanol/dry ice bath was used. For cryo method 1, cryo-sections 
were air-thawed and fixated in 4 % PFA for 5 min first. After two washing steps 
with TBS for 2 × 5 min, sections were permeabilized by incubation in 100 % 
EtOH at -20 °C for 2 min followed by another washing step with TBS for 5 min. 
Afterwards, all steps from the standard protocol, beginning with STEP 3, were 
performed. In the second protocol (cryo method 2), cryo-sections were air-thawed, 
rehydrated in PBS for 2 × 5 min and then permeabilized by incubation in 0.2 % 
Triton X-100 for 5 min. After a washing step in TBS buffer for 5 min, all steps 
from the standard protocol, beginning with STEP 3, were executed. Deviating 
from the standard protocol, serum was diluted in Super-Block and the sections 
were only incubated for 45 min in STEP 5 and the primary antibody was 
incubated for 2 h at 37 °C in STEP 6. For details on primary and secondary 
antibodies, dilutions and serum, see Table 17. 
Immunofluorescent detection of CFTR 
For immunofluorescent staining of CFTR, only cryo-sections from tissue frozen 
with the second freezing method (1 h 2 % PFA RT, 30 % ice-cold sucrose 
overnight and freezing in OCT compound in ethanol/dry ice bath) were used. 
Frozen tissue blocks were processed as described above. Cryo-sections were air-
thawed, rehydrated in PBS for 2 × 5 min and permeabilized in 0.2 % Triton X-100 
for 5 min. After two washing steps with PBS for 5 min, sections were incubated 
with 5 % donkey serum in Super-block for 45 min to reduce non-specific binding. 
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Subsequently, sections were incubated with the primary antibody Ab 596 from the 
CF Foundation, USA (1:50 in Super-Block) for 2 h at 37 °C and washed for 10 
min in PBS. Sections were then incubated with the alexa fluor 488-conjugated 
secondary antibody donkey anti-mouse diluted 1:250 in 2 % pig serum for 1 h. 
From incubation with the secondary antibody onwards, all steps were performed 
in the dark to avoid bleaching of the fluorescence. After a last washing step with 
PBS for 10 min, slides were coverslipped with Vectashield antifade solution 
containing 4',6-diamidino-2-phenylindole (DAPI) for the staining of cell nuclei 
and afterwards stored at 4 °C in the dark. Images were acquired with an inverted 
epifluorescence microscope (Axiovert 200 M; Zeiss, Oberkochen). 
3.8.2. Detection of CFTR by Western Blot 
The applicability of commercially available antibodies for the detection of CFTR 
in protein lysates via Western blot (WB) was evaluated with tissue of a WT piglet, 
human liver tissue and human T84 cells as a positive control and tissue of a 
CFTR-/- piglet as a real negative control. 
Protein isolation from tissue 
40 mg of snap frozen tissue material were transferred to a 12 mL tube containing 
1 mL of protein extraction buffer and was homogenized for 2 min on ice with the 
homogenizer ART-Micra D-8 at 23,500 rpm. To avoid contamination, the rotor 
was cleaned three times with aq. bidest. and once with PBS between different 
samples. Protein extracts were left on ice for 30 min, transferred to 1.5 mL 
Eppendorf tubes and incubated for 15 min at 60 °C. After cooling on ice for 
3 min, the samples were centrifuged at 15,000 rcf for 5 min at 4 °C and the 
supernatant was transferred to a new 1.5 mL Eppendorf tube. Protein lysates were 
stored at -20 °C until further processing. 
Measurement of protein concentration by BCA assay 
To quantify the total amount of protein in the extracted tissue lysates, the 
Bicinchoninic acid (BCA) assay was used. The principle of this method is that the 
protein concentration is indicated by a change of color in the sample solution from 
green to purple in proportion to the protein concentration, which can then be 
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measured photometrically by establishing a calibration curve using protein 
standard solutions of known concentration. 
For this purpose, protein standard solutions of known concentration were prepared 
by a six-fold dilution row (50 µL each) of a BSA stock solution (4 mg/mL) in 
PBS/protein extraction buffer (4:1 v:v). 10 µL of each protein lysate were diluted 
with 40 µL PBS. Bicinchoninic acid was mixed with 4 % CuSO4-solution in a 
ratio of 50:1 and 200 µL of this mixture were pipetted to each standard and 
unknown sample. 100 µL of each reaction mixture were pipetted in duplicates to a 
96 well plate and the plate was incubated at 37 °C for 30 min. Extinction values 
were measured at 562 nm with the SunriseTM microplate reader for ELISA and 
protein concentrations were determined via the standard curve.  
SDS PAGE 
Proteins were separated according to their size by gel electrophoresis. The SDS 
PAGE is based on the principle that sodium dodecyle sulfate (SDS) denatures 
proteins and covers them with a negative charge so that they can be separated 
according to their molecular weight in a polymerized gel matrix when an 
electrical field is applied. 
An 8 % SDS polyacrylamide separating gel was prepared according to Table 11, 
poured into the Mini Protean® Tetra system and covered with a layer of water for 
polymerization. 
Table 11: Composition of 8 % SDS polyacrylamide separating gel. 
aq. dest. 4.63 mL 
1.5 M Tris (pH 8.8) 2.5 mL 
30 % Acrylamid/Bis Solution 2.67 mL 
10 % SDS 100 µL 
10 % APS 100 µL 
Temed 5 µL 
After 45 min, the water was removed carefully, the separating gel was overlaid 
with a 5 % stacking SDS polyacrylamide gel (see Table 12) and a 15-well comb 
inserted at the top.  
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Table 12: Composition of 5 % SDS polyacrylamide stacking gel. 
aq. dest. 3.5 mL 
0.5 M Tris pH 6.8 0.75 mL 
30 % Acrylamid/Bis Solution 0.75 mL 
10 % SDS 50 µL 
10 % APS 50 µL 
Temed 2.5 µL 
During polymerization of the stacking gel, the samples were diluted with 1 × 
Laemmli buffer containing 5 % β-mercaptoethanol and 1 × Laemmli buffer, 
respectively, to a final concentration of 15 µg protein in 18.5 µL of total volume. 
For denaturation, the samples were heated to 60 °C for 15 min. The gel 
electrophoresis chamber was filled with 1 × SDS running buffer and the prepared 
samples were loaded onto the gel. A PageRulerTM prestained protein ladder and an 
unstained Protein Molecular Weight Marker were loaded onto the gel as protein 
weight markers. Electrophoresis ran at 100 V until the proteins, concentrated to a 
narrow band, had entered the running gel, whereupon the voltage was raised to 
140 V. Gel electrophoresis was stopped when the 55 kDa band of the prestained 
protein ladder had leaked from the gel. 
Semi-dry Blot 
Proteins were transferred electrophoretically from the polyacrylamide gel to a 
nitrocellulose membrane via the semi-dry blot method using the Trans Blot® SD 
Semi-Dry transfer cell. Nitrocellulose membranes were activated for 10 min with 
100 % methanol followed by incubation in 1 × transfer buffer for 30 min. The 
polyacrylamide gel was placed on the nitrocellulose membrane, enclosed by two 
extra thick blotting Whatman papers soaked within 1 × transfer buffer, and the 
proteins were blotted to the membrane with 15 V for about 90 min. As 
confirmation of successful blotting, the membranes were stained reversibly with 
Ponceau S solution for 2 min, washed three times with aq. dest. for destaining and 
subsequently stored at 4 °C.  
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Western Immunoblot 
CFTR was detected via antigen-antibody coupling in an immunoblot. All steps 
were conducted in 50 mL falcons in a hybridization oven at room temperature if 
not indicated otherwise. Primary antibodies were diluted in TBS-T-BSA, while 
secondary antibodies were diluted in TBS-T-w/v nonfat dry milk. An overview of 
the standard protocol is given in Table 13. 
Table 13: Standard western blot protocol. 
 Procedure Agent Conditions 
STEP 1 Activation 100 % methanol 1 min 
STEP 2 Washing TBS-T 3 × 5 min 
STEP 3 Blocking TBS-T-w/v nonfat  
dry milk 
1 h 
STEP 4 Washing TBS-T 1 × 15 min, 2 × 5 min 
STEP 5 Primary antibody  4 °C overnight 
STEP 6 Washing TBS-T 1 × 15 min, 2 × 5 min 
STEP 7 Secondary antibody  1 h  
STEP 8 Washing TBS-T 1 × 15 min, 2 × 5 min 




Signals were detected with the ECL detection reagent on HyperfilmTM ECL 
chemiluminescense films in a darkroom. After suitable exposition time, films 
were developed in the Optimax X-ray Film processor 1170-1-0000.  
An overview of the tested antibodies and dilutions is given in Table 18. 
Stripping of the membranes 
If membranes were to be used in further experiments, bound antibodies had to be 
removed by stripping of the membranes. For this purpose, the membranes were 
incubated in elution buffer for 30 min at 70 °C, followed by two washing steps in 
aq. bidest. for 10 min and one washing step in TBS-T in a new falcon for 10 min. 
Afterwards, the membranes could be used for another antibody incubation, 
starting with STEP 3 of the standard protocol.  
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IV. RESULTS 
1. Transgenic expression of CFTR in the intestine modifies 
the severity of meconium ileus in gut-modified CFTR-/- 
piglets 
Since a surgical correction of the fatal intestinal obstruction in newborn CF piglets 
is not feasible to produce large numbers of living animals, we decided to take 
another approach. By transgenic expression of porcine CFTR under the control of 
a promoter selectively expressed in the intestine, the severity of MI should be 
ameliorated and thereby ensure the survival of the CF piglets without affecting the 
other typical organ manifestations. As those pigs should have the potential to 
avoid MI, they are designated as potentially “gut-modified” in the following. 
1.1. Generation of gut-modified CFTR-/- piglets 
Gut-modified CFTR-/- piglets were generated by additive gene transfer of the 
expression vector (see Figure 4) in porcine CFTR-/- kidney cells, followed by 
SCNT and ET. This work was performed by N. Klymiuk, A. Wünsch, 
M. Kurome, V. Zakhartchenko, B. Kessler and T. Güngör, Chair for Molecular 
Animal Breeding and Biotechnology, LMU Munich. 
  
Figure 4: DNA construct for generation of gut-modified CFTR-/- piglets. The 
expression vector consists of different functional parts: a 1.2 kb fragment of the 
porcine fatty-acid binding protein 2 promoter (FABP2) for the selective 
expression in the intestine, a 215 bp long part of the porcine β-hemoglobin (HBB) 
gene to increase the expression capacity by introducing a synthetic intron, the 
4.8 kb coding region of the porcine CFTR followed by the 277 bp long 
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polyadenylation signal of the bovine Growth Hormone (bGH) gene as termination 
signal and a puromycin® (puro®) resistance cassette for positive selection. 
A total of 1401 gut-modified CFTR-/- embryos were transferred to 12 pre-
synchronized sows, resulting in four pregnancies. Three pregnancies went to full 
term with the birth of 13 living and 5 stillborn piglets. The efficiency of NT 
experiments, as defined by the number of living piglets per number of transferred 
embryos and per number of successful embryos, respectively, was about 0.9 % 
and 3.7 %. 25 % of all performed ETs resulted in the birth of living offspring. To 
exclude a potential influence on the outcome of pregnancy rates and the 
phenotype, CFTR-/- kidney cells from different genetic backgrounds were 
employed for additive gene transfer. In the first 11 experiments, cells from a 
cloned CFTR-/- piglet (#1267) and pooled cells from several cloned CFTR-/- 
piglets (#1268, 1270, 1274) were used. In the last NT experiment, pooled cells 
from CFTR-/- piglets (#2353, 2358) produced by normal breeding were employed 
to avoid the negative effects of repeated reproduction by cloning (for details see 
Table 14). 
1.2. Analysis of the intestinal phenotype in gut-modified CFTR-/- piglets 
Immediately after birth, the gut-modified CF piglets were repeatedly treated with 
enemas. Medication for gastric protection and circulation support was applied and 
pancreatic enzymes were supplemented to increase the likelihood of MI removal 
(for details see treatment protocol in Table 1). The gut-modified CF piglets from 
the litter of sow 1 and sow 12 exhibited a clearly impaired viability since birth, as 
they were unable to suckle on their own and had to be fed artificially to ensure 
colostrum and energy intake. The piglets were kept under 24 h surveillance and as 
soon as a piglet started to show a considerably deteriorated behavior, 
characterized by reduced motility, inability to suckle milk and a pear-looking, 
bloated abdomen with enhanced abdominal pressure in the absence of any signs of 
meconium removal, it was euthanized for controlled phenotypical analysis and 
sample collection.  
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All 13 living piglets had to be euthanized within the first 24 h after birth as, in 
spite of all the supportive measures taken, they were not able to remove 
meconium and therefore developed the severe characteristic symptoms mentioned 
above. For a detailed evaluation of the severity, localization and extension of MI 
in comparison to “normal” CF piglets and WT piglets of the same age, see Figure 
5 and  
Figure 6. Summarized, the severity of the intestinal phenotype was improved in 
comparison to normal CF KO piglets in all examined gut-modified CFTR-/- 
piglets. The localization of stuck meconium was consistently found in more distal 
parts of the intestine and in a large percentage of gut-modified CF piglets, 
diverticulosis was less pronounced. 
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Table 14: Results of SCNT experiments using gut-modified CFTR-/- embryos. 
Recipients Genetic background No. of transferred  
embryos 
No. of successful  
embryos 
Pregnancy Result 
Living piglets Stillborn piglets 
Sow 1 #1267 121 121 + 3 (#2128-2130) 3 (#2131-2133) 
Sow 2 #1267 120 - - - - 
Sow 3 #1267 89 - + Preterm abortion 
Sow 4 #1267 99 - - - - 
Sow 5 #1267 111 - - - - 
Sow 6 #1267 136 136 + 6 (#2477-2482) 2 (#2494, 2507) 
Sow 7 #1267 119 - - - - 
Sow 8 #1267 118 - - - - 
Sow 9 #1267 95 - - - - 
Sow 10 #1267 139 - - - - 
Sow 11 #1268, 1270, 1274 159 - - - - 
Sow 12 #2353, 2358 95 95 + 4 (#2736-2739) - 
Total  1401 352 3 13 5 
Efficiency  ~0.9 % ~3.7 % 25 % ~72.2 % ~27.8 % 
Efficiency of NT experiments is calculated as number of living piglets per number of transferred or successful embryos. Pregnancy rate is calculated 
as number of pregnancies resulting in the birth of living piglets per ETs in total. Percentage of living and stillborn piglets, respectively, is calculated 
by correspondent number of piglets per total number of born piglets. 
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Figure 5: Intestinal phenotype of WT, gut-modified CFTR-/- and CFTR-/- 
piglets. (A) Detoriation of the general condition in a gut-modified CF piglet is 
illustrated by the decreased ability to move on its own and a severely bloated 
abdomen with prominent blood vessels (black arrow). (B) View of the intestinal 
convolute after opening the abdominal cavity and after complete resection. White 
asterisks mark the presence of meconium in dilated intestinal loops. In WT 
piglets, meconium has been completely deposited after about 24 h and the 
intestine shows a healthy brownish color and intestinal loops of equal diameter. 
Both in normal and gut-modified CF piglets, intestinal loops are blocked by black 
meconium. Compared to normal CF piglets, the blockage by meconium appears in 
the more distal parts of the intestine in gut-modified CF piglets, extending until 
the beginning of the colon. Discontinuous black arrows point to the cecum, which 
is severely enlarged by stuck meconium in gut-modified CF piglets. The colon is 
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marked by black arrows. Gut-modified CF piglets exhibit the microcolon 
characteristic for normal CF piglets, although a small portion of the meconium 
has entered the proximal parts of the colon ascendens. 
 
Figure 6: Range of MI in WT, gut-modified CFTR-/- (gut CF) and CFTR-/- 
piglets. As a reference point, the cecum is marked by discontinuous black arrows. 
The range of MI (marked by white asterisks) differs in the location between gut-
modified and normal CF piglets. In all examined normal CF piglets, stuck 
meconium is mainly located in the middle and distal parts of the jejunum, whereas 
gut-modified CF piglets exhibit a slightly improved phenotype with meconium 
consistently localized in the distal jejunum, cecum and proximal colon. The 
prominent feature of diverticulosis (black arrow), that is consistently found in all 
normal CF piglets and illustrates the severity of the intestinal phenotype, is 
considerably less pronounced or even missing in gut-modified CF piglets. 
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1.3. Selection of founder animals for recloning 
Founder #2478 had to be euthanized after 24 h due to rapid deterioration of its 
general condition, but no signs of meconium were detected in the intestinal 
convolute and it did not exhibit a microcolon. Therefore, its kidney was explanted 
under sterile conditions, a primary cell line was established and primary kidney 
cells were employed for SCNT and ET. An overview of the recloning experiments 
is given in Table 15. Compared to the results of the generation of gut-modified 
CFTR-/- founder animals by SCNT in Table 14, it has to be mentioned that, 
although the pregnancy rate in the recloning experiments is much higher (55 % 
compared to 25 %), the cloning efficiency, defined as number of living piglets per 
number of successful embryos, is impaired (1.9 % compared to 3.7 %) as well as 
the average number of living piglets per litter (2.6 living piglets/litter compared to 
4.3 living piglets/litter). The percentage of stillborn piglets is increased (35 % 
compared to 27.8 %).  
The recloned piglets were supportively treated and analyzed the same way as the 
gut-modified CFTR-/- founder piglets. All 13 living piglets exhibited a strongly 
reduced viability, were not able to suckle or swallow on their own and had to be 
fed artificially. A high percentage of piglets had enlarged tongues, a well-known 
side effect of SCNT, hindering a self-dependent milk intake (see Figure 7 (A)). 
All 13 piglets had to be euthanized within the first 24 h because of the severe 
deterioration of their general condition due to the characteristic symptoms of the 
severe intestinal phenotype. Close examination of the intestine revealed that the 
improvement of the phenotype in piglet #2478 was not reproducible in recloned 
animals. The range of MI resembled the one found in other gut-modified CFTR-/- 
founder animals, with the main part of the meconium stuck in the distal parts of 
the jejunum and the enlarged cecum. A microcolon was a consistent finding in all 
piglets and diverticulosis was existent in variable degrees (see Figure 7 (B)). 
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Table 15: Recloning experiments of founder #2478. 





No. of successful  
embryos 
Pregnancy Result 
Living piglets Stillborn piglets 
Sow 1 #2478 194 194 + 1 (#2870) 2 (#2869, 2871) 
Sow 2 #2478 118 118 + 1 (#2906) 1 (#2906) 
Sow 3 #2478 119 - - - - 
Sow 4 #2478 152 - - - - 
Sow 5 #2478 187 - - - - 
Sow 6 #2478 135 - - - - 
Sow 7 #2478 122 122 + 2 (#4008, 4009) - 
Sow 8 #2478 127 127 + 4 (#4051-4054) - 
Sow 9 #2478 134 134 + 5 (#4280, 4283-4286) 4 (#4279, 4281, 4282, 4287) 
Total  1288 695 5 13 7 
Efficiency  ~1.0 % ~1.9 % ~55 % 65 % 35 % 
Efficiency of NT experiments is calculated as number of living piglets per number of transferred or successful embryos. Pregnancy rate is calculated 
as number of pregnancies resulting in the birth of living piglets per ETs in total. Percentage of living and stillborn piglets, respectively, is calculated 
by correspondent number of piglets per total number of born piglets. 
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Figure 7: Phenotype of recloned founder piglets. (A) Abnormal findings in 
recloned piglets. All recloned piglets show reduced viability, a high percentage of 
them has an enlarged tongue and the number of stillborn piglets or mummies is 
increased. (B) Intestinal phenotype of two exemplary piglets. The cecum is 
marked with a discontinuous black arrow, the continuous black arrow points to 
the microcolon. The range of MI is marked with white asterisks. Meconium is 
stuck in the distal parts of the jejunum, cecum and the beginning of the colon 
ascendens. All piglets exhibit a microcolon with reduced diameter. Thus, the 
range of MI resembles other founder animals with a slight improvement compared 
to normal CF KO piglets, but not the clearly improved phenotype of #2478. The 
range of diverticulosis differs strongly between all examined recloned piglets.  
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1.4. Analysis of gut-modified CFTR-/- piglets at the genomic level 
Considering the fact that the health of normal CFTR-/- piglets started to deteriorate 
within 24 h after birth because of the severe intestinal phenotype, it was essential 
to establish a rapid method for the genotyping of gut-modified CF piglets, 
including a time-sparing DNA isolation method and an extremely shortened PCR 
protocol. 
DNA isolation 
Three different fast DNA isolation kits were compared in terms of suitability, time 
duration and reliability of PCR results – the nexttecTM Genomic DNA Isolation 
Kit from Tissue and Cells, the Easy-DNATM Kit, protocol #2 – 30 min DNA 
extraction from blood samples and the Isohelix DDK DNA Isolation Kit. 
Table 16: Comparison of DNA isolation methods. 




Nexttec kit Docked 
tail 
Tail docking is routinely 
performed in all litters to 
prevent tail biting 
60 min high 
Easy-DNA 
kit 
Blood Blood collection is 
critical in neonatals 
30 min low 
Isohelix kit Buccal  
swabs 
Easy to handle 90 min medium-high 
After comparing all critical aspects, the DNA isolation from docked tails via the 
nexttec kit proved to be the safest, fastest and most reliable method for the 
isolation of genomic DNA in newborn piglets.  
Establishment of genotyping PCRs 
To confirm the CFTR-/- genotype, two sets of regular PCR amplifying the WT and 
the mutated CFTR sequence were established. The integration of the gut-modified 
CFTR expression vector in the CFTR-/- genome was confirmed by amplifying a 
specific part of the expression vector. As the nexttec DNA isolation protocol is 
very time-saving but produces DNA of inferior quality, a range of primer pairs for 
amplification of the WT (see Figure 8) and mutant CFTR (see Figure 9) sequence 
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had to be tested and best pairs were further optimized. To determine whether the 
gut-modified CFTR expression vector had been integrated in the CFTR-/- genome, 
primer pairs amplifying specific parts of the expression vector in the 3’- and 5’-
UTR-regions flanking the porcine CFTR sequence were tested and the conditions 
were further optimized (see Figure 10). 
 
Figure 8: Testing of primer pairs for the detection of WT CFTR. Primer pairs 
were first tested with an annealing temperature of 58 °C and a starting volume of 
0.5 µL each. DNA isolated with the nexttec 1 h-protocol from WT, CFTR+/- (het) 
and CFTR-/- (hom) piglets served as template. Conditions of promising pairs 
(1 and 12) were optimized by temperature gradient PCR and comparison of 
different primer concentrations. 
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Figure 9: Testing of primer pairs for the detection of mutant (TG) CFTR. 
Primer pairs were first tested with an annealing temperature of 58 °C and a 
starting volume of 0.5 µL each. DNA isolated with the nexttec 1 h-protocol from 
WT, CFTR+/- (het) and CFTR-/- (hom) piglets served as template. Primer pair 6 
detects bands of the wrong size (about 500 bp instead of 960 bp) in the mutant 
animals as well as in the WT animal that serves as negative control. Conditions of 
promising pairs (2 and 9) were optimized by temperature gradient PCR and 
comparison of different primer concentrations.  
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Figure 10: Testing of primer pairs for the detection of the gut-modified 
CFTR expression vector.  Primer pair 1 is located in the 5’-UTR region; the 
other primer pairs are located in the 3’-UTR region of the expression vector. 
Primer pairs were first tested with an annealing temperature of 58 °C and a 
starting volume of 0.5 µL each. DNA from gut-modified CFTR-/- (gutCF) and WT 
piglets isolated with the nexttec 1 h-protocol served as template. Primer pair 3 
also detects a signal in the WT piglets that serve as negative controls. Conditions 
for the promising primer pair 2 were optimized by temperature gradient PCR and 
comparison of different primer concentrations. 
In conclusion, the time necessary for the genotyping of gut-modified CF piglets 
could be minimized to less than three hours between birth and genotyping results, 
including one hour for DNA isolation and one hour for the final genotyping PCRs 
(see Figure 11). DNA isolated with the nexttec 1 h-protocol was of sufficient 
quality for regular genotyping PCR.  
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Figure 11: Example of genotyping gut-modified CFTR-/- (gutCF), WT, 
CFTR+/- (het) and CFTR-/- (hom) piglets.  All three genotyping PCRs detecting 
the WT, the mutant (TG) and the gut-modified (gutCF) CFTR sequence are run 
under the same conditions in one machine. The time duration of all PCR steps was 
minimized as far as possible, until the whole run took about one hour.  
Verification of the correct amplification of the PCR products 
The detection of bands of the correct bp size using the agarose gel electrophoresis 
has to be approved by a further method. To confirm that primers annealed to the 
correct DNA sequences and that the requested base sequences were amplified, 
DNA was eluted from bands of the correct bp size and sequenced via the Sanger 
sequencing approach. The detailed comparison of the base sequences derived 
from sequencing chromatograms to the target sequences revealed that all primers 
annealed correctly to the sequences and that target and amplified sequences were 
identical (see Figure 12). 
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Figure 12: Verification of genotyping PCR products. (A) Electropherograms of 
PCR products amplified with primers for WT, mutant (TG) and gut-modified 
CFTR. In the mutant and WT CFTR chromatograms, the 5’-parts are identical as 
the forward primer Cg2f, which is used for both PCRs, anneals to a part of the 
CFTR sequence present in both sequences. The sequences specific for WT and 
mutant CFTR further downstream are highlighted in red (WT) and yellow (TG). 
(B) Comparison of amplified sequences to target sequences.  
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1.5. Expression analysis of CFTR-/- and WT piglets at the protein level 
For a functional evaluation of the porcine CF model, the absence of CFTR 
expression had to be confirmed at the protein level. Therefore, CFTR expression 
in WT and CF KO piglets was examined by immunohistochemical or 
immunofluorescent approaches and by western blot. A range of commercially 
available primary antibodies are described to detect CFTR in tissue derived from 
pigs. Exclusively in this study, the specificity of the antibodies was evaluated with 
a best-optimal negative control, tissue derived from CF KO animals. 
Detection of CFTR by immunohistochemistry and immunofluorescence 
Initially, the utility of the well-characterized antibody Ab 596 (CF Foundation, 
USA) for the detection of CFTR in cryo-sections from tissue frozen with the 
complicated freezing method 2 was evaluated in IF and IHC, according to a 
published protocol (Stoltz, Rokhlina et al. 2013). However, the primary aim of the 
study was to find an antibody that reliably detected CFTR in paraffin-embedded 
tissue, as the morphology of paraffin-embedded tissue is better preserved and the 
fixation and sectioning works very well compared to cryo-sections. For a detailed 
evaluation of the antibodies, at least one HIER and one PIER method were tested 
using formalin-fixated tissue. As some antibody-specific protocols preferred the 
usage of cryo-sections for IHC, the specificity of all antibodies was also evaluated 
on paraffin slides from methacarn-fixated tissue. Methacarn fixation is reported to 
produce tissue slides with a quality similar to cryo-sections (Mitchell, Ibrahim et 
al. 1985). The specificity of the antibodies from the CF Folding consortium was 
also evaluated using cryo-sections from tissue frozen with freezing method 1with 
cryo method 1, an established protocol for the detection of CFTR in human tissue 
(Kreda and Gentzsch 2011). Table 17 gives an overview of all antibodies, 
fixations and conditions tested in immunohistochemistry. 
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Table 17: Overview of all tested immunohistochemical conditions. 
Primary antibody Fixation Antigen retrieval Dilution Secondary antibody Dilution Serum 
CF Folding 
consortium Ab 528 
Formalin Microwave 1:100; 1:300; 1:900 Biotinylated goat anti-
mouse IgG + 5 % serum 
pig 
1:200 Goat 
Proteinase K 1:200; 1:600 
Methacarn - 1:100; 1:300; 1:900 
Cryo method 1 - 1:250; 1:1,000 Biotinylated AffiniPure 
goat anti-mouse IgG 
1:250 
CF Folding 
consortium Ab 570 
Formalin Microwave 1:100; 1:300; 1:900 Biotinylated goat anti-
mouse IgG + 5 % serum 
pig 
1:200 Goat 
Proteinase K 1:200; 1:600 
Methacarn - 1:100; 1:300; 1:900 
Cryo method 1 - 1:250; 1:1,000 Biotinylated AffiniPure 
goat anti-mouse IgG 
1:250 
CF Folding 
consortium Ab 596 
Formalin Microwave 1:100; 1:300; 1:900 Biotinylated goat anti-
mouse IgG + 5 % serum 
pig 
1:200 Goat 
Water bath 1:300; 1:900; 1:2,700 
Pressure cooker 1:300; 1:900; 1:2,700 
Proteinase K 1:200; 1:600 
Methacarn - 1:100; 1:300; 1:900 
Cryo method 1 - 1:250; 1:1,000 Biotinylated AffiniPure 
goat anti-mouse IgG 
1:250 
Cryo method 2 - 1:300; 1:900 Biotinylated AffiniPure 
goat anti-mouse IgG + 2 % 
serum pig 
1:250 
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CF Folding 
consortium Ab 660 
Formalin Microwave 1:100; 1:300; 1:900 Biotinylated goat anti-
mouse IgG + 5 % serum 
pig 
1:200 Goat 
Proteinase K 1:200; 1:600 
Methacarn - 1:100; 1:300; 1:900 
Cryo method 1 - 1:250; 1:1,000 Biotinylated AffiniPure 
goat anti-mouse IgG 
1:250 
CF Folding 
consortium Ab 769 
Formalin Microwave 1:100; 1:300; 1:900 Biotinylated goat anti-
mouse IgG + 5 % serum 
pig 
1:200 Goat 
Proteinase K 1:200; 1:600 
Methacarn - 1:100; 1:300; 1:900 
Cryo method 1 - 1:250; 1:1,000 Biotinylated AffiniPure 
goat anti-mouse IgG 
1:250 
Abcam CF3 Formalin Microwave 1:100; 1:300; 1:900; 1:1,500; 
1:1,800; 1:3,000; 1:6,000; 
1:12,000 
Biotinylated goat anti-
mouse IgM + 2 % serum 
pig 
1:100 Goat 
Water bath 1:1,500; 1:3,000; 1:6,000; 
1:12,000 
Proteinase K 1:1,500; 1:3,000; 1:6,000; 
1:12,000 
Methacarn - 1:100; 1:300; 1:900; 1:1,500; 
1:1,800; 1:3,000; 1:6,000; 
1:12,000 
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Cell Signaling #2269 Formalin Microwave 1:100; 1:300; 1:900 Biotinylated goat anti-
rabbit IgG + 5 % serum 
pig 
1:200 Goat 
Proteinase K 1:300 
Methacarn - 1:100; 1:300; 1:900 
R&D 24-1 Formalin Microwave 1:25; 1:75; 1:250 Biotinylated goat anti-
mouse IgG + 5 % serum 
pig 
1:200 Goat 
Water bath 1:150; 1:300; 1:900 
Pressure cooker 1:150; 1:300; 1:900 
Proteinase K 1:100; 1:350 
- 1:100; 1:200; 1:500 
Methacarn - 1:100; 1:300; 1:900 
Santa Cruz H 182 Formalin Microwave 1:100; 1:300; 1:900 Biotinylated goat anti-
rabbit IgG + 5 % serum 
pig 
1:200 Goat 
Proteinase K 1:50; 1:100; 1:200; 1:300 
Methacarn - 1:100; 1:300; 1:900 
Santa Cruz N-20 Formalin Microwave 1:100; 1:300; 1:900 Biotinylated rabbit anti-
goat IgG + 5 % serum pig 
1:200 Rabbit 
Proteinase K 1:50; 1:150; 1:450 
Methacarn - 1:100; 1:300; 1:900 
The single method specifically detecting CFTR is marked in red. 
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Staining with the primary antibody Ab 596 (CF Foundation, USA) of cryo-
sections derived from tissue frozen with the complicated freezing method 2 
worked reliably using cryo method 2 for the specific detection of CFTR in 
intestinal tissue both in IF and IHC (see Figure 13 and Figure 14). Staining 
patterns in IF and IHC were identical. 
In WT animals, CFTR was strongly expressed in the crypts of the intestine and 
showed a decreasing gradient along the villi from the crypts to the villous top. 
Several single villous cells with normal enterocyte-like morphology, presumably 
an equivalent to the CFTR High expresser cells found in human and rat proximal 
small intestine (Jakab, Collaco et al. 2013), showed a strong CFTR signal. In the 
staining with IF detection, fetal faeces showed a strong autofluorescence, a feature 
that was reproduced using IHC, where fetal faeces were stained in brown in the 
negative control. In WT lung tissue, a very weak CFTR signal was detected in the 
submucosal glands, whereas the respiratory epithelium was not stained. In CF KO 
animals, CFTR was neither detected in intestinal nor in lung tissue. Staining with 
antibody Ab 596 confirmed thereby the absence of any CFTR protein in the 
CFTR-/- piglets. 
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Figure 13: Immunofluorescent detection of CFTR in the intestine of WT and CFTR-/- piglets with Ab 596.  Images show staining for cell nuclei 
(DAPI, blue) and CFTR (red). Intestinal crypts are marked with a white arrow. In WT piglets, CFTR is mainly localized in the intestinal crypts with a 
decreasing gradient along the villous axis and strong staining of single villous cells. In CF KO piglets, CFTR is not detected, faeces show a strong 
autofluorescence (marked with white asterisks). 
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Figure 14: Immunohistochemical detection of CFTR in WT and CFTR-/- 
intestine and lung with Ab 596. (A) Detection of CFTR in the intestine of WT 
and CF KO piglets. Intestinal crypts are marked with black arrows. The 
discontinuous arrow points to a single strongly-stained cell. Negative controls 
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(neg) are stained with the secondary antibody only. Faeces are stained in brown 
both in the stained slide and the negative control of the CF KO intestine (marked 
with black asterisks). (B) Detection of CFTR in the lung from WT and CF KO 
piglets. Black arrows point to submucosal glands. 
Since the detection of CFTR on cryo-sections with Ab 596 was not sensitive 
enough to detect CFTR in lung tissue and the tissue morphology showed freezing 
artefacts in spite of the cryo-protective freezing process, several commercially 
available antibodies for the detection of CFTR on paraffin-embedded tissue were 
tested. As the lung is the major organ of interest in CF, the antibodies were first 
evaluated on lung tissue from WT and CFTR-/- piglets (see Figure 15). Two 
antibodies showed an obvious difference of staining pattern between WT and CF 
KO piglets, all other antibodies detected no specific signal. Ab 596 (1:900, HIER 
by water bath) showed strong apical cytoplasmatic staining of the respiratory 
epithelium and very weak staining of the submucosal glands in formalin-fixated 
WT lung tissue, whereas the CF KO lung tissue was negative (see Figure 15 (B)). 
Ab 24-1 (1:900, HIER by pressure cooker) recognized a weak apical 
cytoplasmatic signal of the respiratory epithelium and submucosal glands with 
very strong staining on the apical surface of the respiratory epithelium in 
formalin-fixated WT tissue, while CF KO tissue was negative (see Figure 15 (D)). 
However, when these two antibodies were employed under the same conditions 
for the detection of CFTR in intestinal tissue, they detected the same staining 
pattern both in WT and CF KO tissue (see Figure 16). To exclude a single animal-
specific effect, both antibodies were tested with the same conditions on a larger 
number of WT and CF KO animals. As the unspecific staining on intestinal tissue 
was reproducible for all tested animals, these antibodies were not suitable for a 
specific detection of CFTR. None of the other evaluated antibodies detected a 
specific CFTR signal in WT and simultaneously no signal in CF KO piglets in 
lung and intestinal paraffin-embedded tissue. Either the signal pattern was 
completely unspecific with strong staining of the wrong tissue, e.g. smooth 
muscle (see Figure 15 (C)), or the expression pattern seemed correct, however, 
with no difference between WT and CF KO animals. Cryo method 1 did not give 
a specific signal for CFTR, when porcine tissue was used. 
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Figure 15: Testing of antibodies on paraffin-embedded lung tissue from WT 
and CFTR-/- piglets. (A) Ab 528 (CF Foundation, USA), 1:900 on methacarn-
fixated lung tissue. (B) Ab 596 (CF Foundation, USA), 1:900 on formalin-fixated 
lung tissue with HIER by water bath. (C) Ab CF3 (abcam, UK), 1:12,000 on 
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formalin-fixated tissue with PIER by proteinase K. (D) Ab 24-1 (R&D systems, 
Wiesbaden), 1:900 on formalin-fixated tissue with HIER by pressure cooker. 
 
Figure 16: Unspecific staining of CFTR in the intestine of WT and CFTR-/- 
piglets. (A) IHC on formalin-fixated intestinal tissue with HIER by water bath 
using Ab 596 in a dilution of 1:900. The staining shows the correct pattern, with 
main localization in the intestinal crypts (marked with a black arrow), but WT and 
CF KO slides show no difference in staining patterns. (B) IHC on formalin-
fixated intestinal tissue with HIER by pressure cooker using ab 24-1 in a dilution 
of 1:900. Staining shows the correct pattern, but no difference between WT and 
CF KO tissue. 
Detection of CFTR by western blot 
The aim of this study was to evaluate whether commercially available antibodies 
for the detection of CFTR in WB can specifically recognize CFTR in native tissue 
derived from WT and CF KO piglets. For testing the sensitivity of the antibodies, 
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protein lysates from pig organs with high (proximal jejunum) and low (lung and 
heart) expression levels of CFTR were employed for analysis. As all antibodies 
were designated to detect human CFTR, human liver and T84 cells, a human 
colon carcinoma cell line with endogenous CFTR expression levels, were 
additionally used as positive controls. Table 18 gives an overview of the tested 
primary and secondary antibodies with correspondent dilutions. 
None of the tested antibodies specifically recognized the two typical CFTR bands 
(B band and C band) at about 150 kDa and 180 kDa in porcine tissue lysates. The 
B band indicates the presence of the core-glycosylated form of the protein and the 
C band the fully-glycosylated mature form of CFTR (Farinha, Penque et al. 
2004). Either no bands of the correct size were detected (see Figure 17 (B)) or 
bands of the correct size were also detected in the negative control, tissue derived 
from the CF KO piglet (see Figure 17 (A)). Only one antibody, Ab 24-1 (R&D 
systems, Wiesbaden) gave a specific signal for the detection of endogenous levels 
of human CFTR in human T84 cells (see Figure 17 (A)). 
Table 18: Overview of tested western blot conditions. 
Primary antibody Dilution Secondary antibody Dilution 
CF Folding 
consortium Ab 528 
1:1,000 HRP goat anti-mouse IgG 1:5,000 
CF Folding 
consortium Ab 570 
1:1,000 HRP goat anti-mouse IgG 1:5,000 
CF Folding 
consortium Ab 596 
1:2,000 HRP goat anti-mouse IgG 1:5,000 
CF Folding 
consortium Ab 660 
1:750 HRP goat anti-mouse IgG 1:5,000 
CF Folding 
consortium Ab 769 
1:1,000 HRP goat anti-mouse IgG 1:5,000 
Cell Signaling #2269 1:1,000 HRP goat anti-rabbit IgG 1:2,000 
Abcam CF3 1:1,500 HRP goat anti-mouse IgG 1:5,000 
R&D 24-1 1:400 HRP goat anti-mouse IgG 1:5,000 
Santa Cruz H 182 1:1,200 HRP goat anti-rabbit IgG 1:2,000 
Santa Cruz N-20 1:200 HRP mouse anti-goat IgG 1:5,000 
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Figure 17: Detection of CFTR by WB. (A) Detection of CFTR with antibody 
R&D 24-1. The sharp B band and C band (red arrows) typical for the core- and 
fully glycosylated CFTR protein are detected in protein lysate from human T84 
cells. In porcine tissue, bands of the size of the C band are detected both in WT 
and CF KO piglets. (B) Detection of CFTR with antibody Ab 528. No bands of 
the correct size are detected. 
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1.6. Expression analysis of gut-modified CFTR-/- piglets at the RNA level 
The detection of endogenous CFTR protein levels by immunological methods 
proved to be difficult, limited by both specificity and sensitivity of the available 
antibodies. Thus, the expression levels of CFTR were examined at the more 
sensitive mRNA level. To assess whether gut-modified CFTR is transcribed into 
mRNA and whether gut-modified CFTR transcripts are restricted to the intestine, 
the expression level of gut-modified CFTR in different parts of the intestine, lung, 
trachea, heart, liver, kidney and pancreas was measured using qPCR. To 
determine the expression levels of CFTR in WT animals, another qPCR was set 
up for the detection of endogenous CFTR transcripts. In addition, gut-modified 
CFTR expression was compared to the transcript level of FABP2, whose promoter 
was used to drive the transgene. To enable a comparison between different 
animals and organs, the expression of TBP2, a lowly expressed housekeeping 
gene coding for the transcription factor TATA-box binding protein 2, was 
determined. 
The comparison of two methods for the isolation of RNA from tissue, the RNA 
isolation with Trizol® and the Direct-zol™ RNA MiniPrep Kit revealed that the 
purity and concentration of the extracted RNA was higher when RNA was 
isolated with Trizol®. The quality of RNA and cDNA was controlled at different 
levels. RNA concentration and purity were measured with a photometer and only 
if the ratios for the wavelengths 260 nm/ 280 nm and 260 nm/ 230 nm were above 
1.8 and 1.9, respectively, the RNA was employed for cDNA synthesis. The 
integrity of RNA was assessed by electrophoresis on a denaturating RNA gel; 
RNA of good overall quality exhibited sharp 28S and 18S ribosomal RNA bands 
with an approximate intensity of 2:1 under UV light. Degraded RNA appeared as 
a smear and was not employed for any further analysis (see Figure 18 (A)).  
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The integrity of cDNA and the possible contamination with gDNA was assessed 
in a PCR amplifying a part of the ubiquitously expressed housekeeping gene beta-
actin. Compared to the RevertAid Reverse Transcriptase, the intensity of bands in 
the control actin-PCR on cDNA appeared stronger when the SuperScriptTM III 
Reverse Transcriptase was used for cDNA synthesis, implying a more efficient 
reverse transcription. Only if sharp bands were detected in the samples containing 
cDNA template and the samples containing the DNase digest were clearly 
negative, cDNA was employed for further qPCR analysis (see Figure 18 (B)). 
 
Figure 18: Quality assessment of RNA and cDNA. (A) Assessment of RNA 
integrity using a denaturating RNA gel. Overall quality of loaded RNA samples 
appears to be good, as sharp 28s and 18s bands in an approximate ratio of 2:1 are 
visible. (B) beta-actin PCR on cDNA and corresponding DNase digest templates. 
cDNA as template gives sharp bands, whereas DNase digest samples are negative, 
indicating no contamination with gDNA.  
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Primers for qPCR were first evaluated in endpoint-PCR. Primers for the detection 
of gut-modified CFTR were already tested for genotyping (see Figure 10) and the 
utility of primers for the amplification of TBP2 was already proven in previous 
studies. Primers for the detection of CFTR were designed to anneal to the 3’-UTR 
or 5’-UTR regions of CFTR that are distinct between endogenous and transgenic 
CFTR. However, all primers tested for the detection of endogenous CFTR also 
amplified unspecific products and were therefore not suitable for the 
determination of endogenous CFTR (see Figure 19 (A) and (B)). Therefore, the 
exon-spanning primers Lars2f and Lars2r, lying within the coding region of 
CFTR, were utilized, enabling a direct comparison of CFTR expression between 
WT and gut-modified CF animals (see Figure 19 (C)). For the detection of FABP2 
expression, exon-spanning primers were evaluated (see Figure 20) and the best 
primer pair 6, FEqf2 and FEqr3 was finally utilized for qPCR. 
Final conditions such as primer volumes, annealing temperature and duration of 
PCR steps were optimized in the qPCR by comparing the slopes of standard 
curves that were calculated from serial dilutions of cDNA templates. If the linear 
regression analysis showed a high coefficient of determination (R2 > 0.98) and the 
slope of the standard curve was approximately -3.32 (equivalent to an 
amplification efficiency of 100 %), these conditions were used for the 
determination of the correspondent genes. Final optimized conditions are given in 
Table 19. 
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Figure 19: Testing of primer pairs for the detection of CFTR in qPCR. Primer 
pairs were first tested with an annealing temperature of 58 °C and a starting 
volume of 0.5 µL each. (A) Primer pairs for the detection of endogenous CFTR 
were tested first with WT gDNA as template. (B) Specificity of promising primer 
pairs was evaluated with gDNA from WT and CFTR-/- piglets (hom) as template. 
All primer pairs amplify a product both in WT and CFTR-/- piglets. (C) Exon-
spanning primer pairs 9 and 10 are designed to amplify products lying within the 
coding region of CFTR. Primer pair 10 detects a specific band in cDNA isolated 
from WT intestine (duodenum (Duo), proximal jejunum (prox Jej) and distal 
jejunum (dist Jej)), but not in gDNA or in cDNA from the duodenum of CFTR-/- 
piglets (hom Duo). 
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Figure 20: Testing of primer pairs for the detection of FABP2 in qPCR. 
Primer pairs were first tested with an annealing temperature of 58 °C and a 
starting volume of 0.5 µL each. Exon-spanning primers were tested with WT 
cDNA from intestinal tissue material (proximal jejunum (prox Jej) and distal 
jejunum (dist Jej)). 
Table 19: Final conditions for qPCR. 
Gene Primer pair Concentration Annealing 
temperature 
Annealing time 
TBP2 tbpf/tbpr 0.7 µL 63 °C 60 s 
FABP2 FEqf2/FEqr3 0.3 µL 60 °C 30 s 
gutCFTR CFgutf2/CFgutr2 0.6 µL 65 °C 30 s 
CFTR Lars2f/Lars2r 0.8 µL 63 °C 60 s 
The expression level, measured in copies per ng RNA inserted into cDNA 
synthesis, was calculated for each examined gene from Ct -values and the PCR 
efficiency derived from the slopes of standard curves. The measurement of the 
expression of the housekeeping gene TBP2 served as internal quality control. 
Especially the integrity of cDNA from pancreatic tissue was evaluated on the 
basis of the TBP2 expression. If no TBP2 expression was detected in a specific 
organ sample, the cDNA was not further analyzed. The expression of TBP2 was 
approximately within the same range of several hundred copies per ng RNA for 
all examined organs and genotypes (see Figure 21). 
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Figure 21: Expression levels of TBP2 in different organs and genotypes. 
Expression levels of TBP2 in copies per ng RNA inserted in cDNA synthesis are 
calculated from Ct-values and PCR efficiency. The exemplary graphs show that in 
cDNA from pancreatic or tracheal tissue of several animals no expression of 
TBP2 is detected, meaning that cDNA synthesis unsuccessful. 
The FABP2 expression was investigated for the evaluation of the utility as 
intestine-specific promoter for the gut-modified construct. The expression pattern 
of FABP2 did not differ among different genotypes. As expected, expression 
levels lying within a range of several hundred to several thousand copies per ng 
inserted RNA could be detected throughout the small intestine. Expression levels 
increased from the duodenum to the proximal parts of the jejunum, where the 
highest levels of mRNA expression were determined. From the proximal jejunum 
to the ileum, a clear decline of the FABP2 expression was observed (see Figure 
22). In the other examined organ systems, as well as in the colon, no quantifiable 
amount of transcripts was measured. It is of note; that FABP2 expression was 
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consistently higher in the intestine of CF KO or gut-modified CF piglets, 
correlating with the suggested suitability of increased FABP2 levels as marker for 
epithelial intestinal damage (Schellekens, Grootjans et al. 2014). 
 
 
 Figure 22: Expression levels of FABP2 in different organs and genotypes. 
Expression levels of FABP2 in copies per ng RNA inserted in cDNA synthesis are 
calculated from Ct -values and PCR efficiency. FABP2 expression shows a 
consistent pattern throughout all examined genotypes. Expression levels increase 
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from duodenum to proximal jejunum, where the highest levels are detected, and 
decrease up to the ileum. In the colon, no quantifiable expression can be 
measured. 
Expression levels of the gut-modified CFTR construct were examined in eight 
founder animals and two recloned piglets. In WT and CF KO piglets, no 
quantifiable amount of expression was detected. In five founder animals (#2128, 
2130, 2477, 2480 and 2482) and in the recloned piglets (#2870 and 2906), 
expression of gut-modified CFTR was limited to the small intestine, with the 
highest expression levels in the proximal parts. This expression level 
corresponded to the expression of FABP2. Three founder animals (#2129, 2479 
and 2736) showed expression of the gut-modified construct throughout all the 
examined organ systems, although the expression levels in the intestine were 
higher compared to other organs (see Figure 23). 
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 Figure 23: Expression levels of gut-modified CFTR in founder animals and 
recloned piglets. Expression levels of gut-modified CFTR in copies per ng RNA 
inserted in cDNA synthesis are calculated from Ct -values and PCR efficiency. In 
founder #2477 and recloned piglet #2906, the expression of gut-modified CFTR is 
limited to the small intestine (duodenum, proximal and distal jejunum and ileum). 
Founder #2129 shows expression in all examined organs, with the highest levels 
in the proximal jejunum. 
For direct comparison of CFTR expression in WT and gut-modified CF animals, 
the expression of a part of the coding region found in both genotypes was 
analyzed. In CF KO animals, no CFTR expression was measurable. The overall 
expression level of CFTR in WT animals was relatively low, lying within a range 
of several hundred copies per ng inserted RNA for the proximal parts of the small 
intestine, where the highest expression levels were detected. The whole intestine 
was the organ with the highest expression levels, showing a strong decline from 
the duodenum to the colon (see Figure 24 (A)). In the airways, only very small 
amounts of CFTR were expressed. CFTR expression in gut-modified CFTR-/- 
piglets corresponded to the expression of gut-modified CFTR in terms of organ 
expression patterns. In five founder animals (#2128, 2130, 2477, 2480 and 2482) 
and in the recloned piglets (#2870 and 2906), expression of CFTR was limited to 
the small intestine. Three founder animals (#2129, 2479 and 2736) showed 
expression of CFTR in all examined organs. CFTR expression levels were 
negatively correlated with the severity of the intestinal phenotype. Founder #2477 
and recloned piglet #2906 showed the strongest CFTR expression levels of all 
examined animals. The correlation of CFTR expression pattern and expression 
levels of these two animals with their intestinal phenotype revealed that the 
severity of MI was less pronounced when the expression levels of CFTR were 
higher in the distal parts of the small intestine (see Figure 24). However, even in 
these piglets, the expression levels of CFTR were not sufficient to rescue them 
from the lethal intestinal obstruction and to ensure their survival.  
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Figure 24: Comparison of CFTR expression levels to the intestinal phenotype. 
(A) Expression levels of CFTR in the intestinal tract of WT piglets and the two 
highest-expressing gut-modified CF piglets. Expression levels of CFTR in copies 
per ng RNA inserted in cDNA synthesis are calculated from Ct -values and PCR 
efficiency. In the WT piglet, CFTR expression levels decrease from duodenum to 
colon. Piglet #2477 shows the highest levels in the distal parts of the small 
intestine, in piglet #2906, expression levels of CFTR are the highest in the 
proximal parts of the small intestine. (B) Correlation of CFTR expression with 
intestinal phenotype. The cecum is marked with a black arrow, asterisks indicate 
the localization of MI. The discontinuous black arrow points to the microcolon. In 
piglet #2477, meconium has passed through the normal-sized cecum and is stuck 
in the colon with a normal diameter, in piglet #2906, the meconium is stuck in the 
distal parts of the jejunum and the enlarged cecum, the colon appears atretic. 
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To confirm that primers used for qPCR amplified the correct products, a melt 
curve analysis was performed following each qPCR run (data not shown) and the 
PCR products were sequenced via the Sanger approach (see Figure 25). The 
correct amplification of the primers used for the determination of gut-modified 
CFTR had already been proven. All amplified sequences showed 100 % identity 
with the target sequences. Sequencing confirmed that very low levels of FABP2 
are also expressed in other organs apart from the intestine. 
 
Figure 25: Sequencing of qPCR products.  (A) Extract of electropherograms 
from the sequenced qPCR products. (B) Comparison of amplified sequences and 
target sequences.  
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2. Modifier genes contribute to the severity of meconium 
ileus in CFTR-/- piglets 
As is known, the severity of the intestinal phenotype in human CF patients is 
strongly influenced by modifier genes either increasing or decreasing the 
susceptibility for MI (Blackman, Deering-Brose et al. 2006). Therefore, the 
second approach for the rescue of the lethal intestinal phenotype in CF KO piglets 
was to study if modifier genes might also play a role in the development of MI in 
the porcine CF model. 
2.1. Establishment of a breeding herd for the production of WT, 
CFTR+/- and CFTR-/- piglets 
In order to examine whether there was a naturally occurring variability in the 
severity of MI in CF KO piglets, the intestinal phenotype of a large number of CF 
KO piglets had to be analyzed. By selective mating of female and male CFTR+/- 
pigs, litters containing piglets of all genotypes were produced for different 
collaboration projects. To minimize inbreeding, mating between littermates was 
avoided if possible. In 35 litters with 10.4 animals per litter on average, a total of 
364 piglets were born. Approximately following the Mendelian rules, 99 piglets 
were WT (27.2 %), 91 piglets were CF KO (25 %) and 174 piglets were CFTR+/- 
(47.8 %). It is of note, that in contrast to data reported for male humans carrying 
one CFTR mutation (Mak, Zielenski et al. 1999), we could not observe any 
problems with reduced fertility or infertility in the CFTR+/- breeding boars. 
 
Experiments on mucus transport in explanted WT and CFTR-/- airways 
The main part of CF piglets was produced, genotyped and used for tissue 
sampling to study mucociliary clearance in explanted tracheas by Anna Ermund 
and Gunnar C. Hansson from the Mucin Biology Group at the University of 
Gothenburg. The video microscopy imaging of living tracheal tissue showed that 
the airways were cleaned by mucus in strands that move towards the larynx and 
not by a continuous mucus layer. In CF KO airways, mucus strands are 
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transported with a much slower velocity compared to WT airways - a feature that 
can be imitated in WT airways when bicarbonate is removed from the Krebs 
buffer (see Figure 26). 
 
Figure 26: Video microscopy imaging of living WT and CFTR-/- tracheal 
tissue. (A) Mucociliary clearance in living tracheal tissue; first and last frame 
from video microscopy imaging. Mucus is stained by Alcian blue, arrows of the 
same color point to identical strands. Mucus does not form a continuous layer but 
forms strands. Within a period of 5 min, mucus strands have moved in the WT 
trachea but not in the trachea of CF KO piglets. (B) Calculation of transport 
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velocity of strands. Statistics calculated with Kruskal-Wallis non-parametric test. 
Each data point represents the mean of several time lapses of one animal. Data 
provided by Anna Ermund, Mucin Biology Group, University of Gothenburg. 
Mucus strands are secreted by submucosal glands and should therefore mostly 
consist of Mucin 5b (Muc5b), that is expressed by mucous cells in the submucosal 
glands and by goblet cells of the surface epithelium (Meyerholz, Lambertz et al. 
2015). However, immunofluorescent studies with antibodies for Mucin 5ac 
(Muc5ac) and Muc5b and scanning electron microscopy revealed that mucus 
strands released by submucosal glands were coated by mucus from goblet cells of 
the surface epithelium. As goblet cells mainly express Muc5ac, similar amounts 
of Muc5ac and Muc5b are found in the airway mucus. In terms of mucus 
secretion and mucin contents, WT and CF KO mucus in the trachea do not differ 
(see Figure 27). 
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Figure 27: Secretion and composition of airway mucus. (A) Muc5b and 
Muc5ac staining of WT and CF KO trachea. Nuclear counter stain is performed 
with Hoechst. Both in WT and CF KO trachea, Muc5b is expressed mainly in 
mucous cells from submucosal glands (marked with white asterisks), but also in 
goblet cells of the surface epithelium (marked with red asterisks), Muc5ac is 
expressed by goblet cells. In both genotypes, mucus strands contain Muc5b and 
Muc5ac. (B) SEM of WT airways. Mucus strands are released from submucosal 
glands (A), strands in contact with goblet cells are marked with black arrow (B). 
Muc5b strands (marked with green arrow) are coated with Muc5ac (marked with 
red arrow) (C). Data provided by Anna Ermund, Mucin Biology Group, 
University of Gothenburg. 
2.2. Finding CFTR-/- piglets with an improved intestinal phenotype 
Among a total of 91 CF KO piglets that had been produced by conventional 
breeding, we found three piglets (#2850, 3137 and 4424) that showed a clearly 
improved intestinal phenotype when examined after sacrificing. In these piglets, 
the meconium had passed through the cecum and was stuck in the middle to distal 
parts of the colon. In addition, the size and diameter of the colon was similar to a 
WT colon with no signs of a microcolon and no diverticulosis at the mesenterial 
side of the intestine was detected (see Figure 28). To clarify the relevance of the 
genetic background for this naturally occurring considerable improvement of the 
intestinal phenotype, we followed two distinct strategies, one hypothesis-driven 
“candidate gene” approach and the unbiased “whole-genome” approach. We 
tested if mutations in the CLCA4b gene might have an impact on the severity of 
MI and searched for single nucleotide polymorphisms (SNPs) in a genome-wide 
analysis of the three improved piglets and other CF KO animals.  
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Figure 28: Improved intestinal phenotype in CFTR-/- piglets. (A) Features of 
improvement. Small parts of the meconium are removed naturally (black arrow 
points to removed meconium) and no herniation of mucosa is detected at the 
mesenterial side of the intestine. After opening the abdomen, it becomes obvious 
that the cecum (white arrow) is enlarged but filled with milk, and meconium is 
visible in the colon gyri (white asterisks). (B) Intestine laid out in full length. 
Meconium passed through the cecum (black arrow) and milk is found in the 
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proximal to middle parts of the colon (black asterisks). The diameter of the colon 
is enlarged in comparison to “normal” CF KO piglets. 
Influence of CLCA4b integrity on meconium ileus severity in CFTR-/- piglets 
CLCA4 is known to modulate residual chloride conductance in the intestine of 
human CF patients (Kolbe, Tamm et al. 2013). In the pig genome, a naturally 
occurring duplication, CLCA4b, occurs, that is especially abundant in intestinal 
cells and co-expressed with CFTR. A large percentage of the pig population has a 
deleterious mutation within this gene. The 10 bp deletion leads to a loss of the WT 
splice acceptor site in intron 7, resulting in alternative splicing to a sequence 
38 bp upstream of exon 8. This causes a frameshift in protein translation and 
generates a premature stop codon in exon 8 (see Figure 29 (A)) (Plog, Klymiuk et 
al. 2015). We examined if there was correlation between the CLCA4b integrity 
and the improved intestinal phenotype in the three CF KO piglets. Three primer 
pairs amplifying the region containing the mutation were compared and primer 
pair CLCA4b2f/CLCA4b2r was ultimately utilized for PCR (see Figure 29 (B)). 
Sequencing the candidate region of CLCA4b in two of the three improved CF KO 
piglets (#2850 and #3137) and 15 other CF KO piglets revealed that piglet #2850 
was homozygous for the deletion in CLCA4b, whereas piglet #3137 was 
heterozygous. Three other examined CF KO piglets without improved phenotype 
were homozygous for the deletion, eight heterozygous and in four CF KO piglets 
only WT alleles were detected. These results indicate that the deletion in CLCA4b 
has no effect on the severity of MI and that CLCA4b is therefore no potential 
modifier gene for the intestinal phenotype in the porcine CF model.  
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Figure 29: Sequencing of the candidate region in CLCA4b.  (A) Deletion in 
CLCA4b causes alternative splicing (WT and cryptic splice acceptor sites are 
marked with a black and red arrow, respectively) and the transcription of a protein 
with a premature stop codon (marked with asterisk). (B) Testing of primers for the 
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amplification of the region of CLCA4b holding the deleterious mutation. Primers 
were tested first with a volume of 0.5 µL each and an annealing temperature of 
58 °C. Conditions for the PCR utilizing primer pair 2. (C) Excerpt of 
electropherograms from WT, heterozygous and homozygous piglets. For 
sequencing purposes, the reverse primer CLCA4b2r was used. Regions at the 5’- 
and 3’-side of the deletion (10 bases missing in the mutant sequence are 
highlighted in blue) are highlighted in yellow and red. In the piglets heterozygous 
for the mutation, characteristic double peaks (see black arrow) are seen at the 5’-
side of the red sequence. The first two red peaks at position 68 and 69 are distinct 
as the first bases at the 3’-side in both the deletion and the yellow sequence are 
thymidine. 
Finding candidate loci that are linked to the improved intestinal phenotype 
For a precise description of the degree of relationship between the three CF KO 
piglets with the improved intestinal phenotype, a pedigree containing all the 
ancestors and littermates of these three piglets was created. DNA was isolated 
from the three piglets, all CF KO littermates and the parents and grandparents if 
stored tissue samples were available and subsequently employed for a genome-
wide survey of single nucleotide polymorphism (SNP) variations using the 
PorcineSNP60 DNA Analysis Kit v2 (Illumina, USA). SNP typing was performed 
by Doris Seichter, Tierzuchtforschung e.V. München (TZF Grub, Germany) and 
data was analyzed by Sophie Rothammer and Ivica Medugorac, Chair of Animal 
Genetics and Husbandry, Faculty of Veterinary Medicine, LMU Munich. 
SNP typing revealed that there are two potential modifier loci on chromosome 10 
(25.8–25.9 Mb) and on chromosome 16 (4.7–5.2 Mb). The three improved piglets 
showed homozygosity for a specific haplotype at both loci. CF KO piglets #3343 
and #3344 were homozygous for the same haplotype detected in the three 
improved piglets on chromosome 10 but not on chromosome 16. CF KO piglets 
#3142, #3146 and #3539 were homozygous for the same haplotype detected in the 
three improved piglets on chromosome 16, but not on chromosome 10 (see Figure 
30). This finding indicates that the severity of the intestinal phenotype might be 
improved in CF KO piglets that are homozygous for specific haplotypes both on 
chromosome 10 and chromosome 16. 
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Figure 30: Pedigree and SNP-typing of three CFTR-/- piglets with improved 
intestinal phenotype. The three improved CF KO piglets #2850, #3137 and 
#4424 are highlighted in red. Filled and empty boxes indicate the haplotypes of 
the two alleles (the potential locus on chromosome 10 is highlighted in red, the 
potential locus on chromosome 16 in purple). The three improved piglets are the 
only CF KO piglets that are homozygous for a specific haplotype (filled box) for 
both events. 
As we assumed that two separate autosomal recessive events had to combine in 
order to achieve an improvement of the intestinal phenotype in CF KO piglets, the 
probability to generate these improved CF KO piglets by mating of CFTR+/- pigs 
was calculated according to Mendelian rules. Only 25 % of a litter are CF KO 
piglets, therefore, the probability that a piglet is both a CF KO and homozygous 
for the SNPs found on chromosome 10 and 16, is very low if the parents are not 
selected for the specific haplotypes (see Table 20). For an efficient production of 
CF KO piglets that are homozygous for both potential modifiers, it is important 
for future breeding attempts that all pigs of the breeding herd will be screened for 
the two candidate loci. 
Table 20: Influence of the parents’ genotype on the probability to generate 
CFTR-/- piglets with an improved intestinal phenotype. 




for both events 
(A/A; B/B) 
Probability for CF 
KO piglets 
homozygous for both 
events (A/A; B/B) 
P1: A/a; B/b 
P2: A/a; B/b  
6.25 % ~1.56 % 
P1: A/A; B/b  
P2: A/a; B/b 
12.5 % ~3.13 % 
P1 A/A; B/b 
P2: A/A; B/b 
P1: A/A; B/B 
P2: A/a; B/b 
25 % 6.25 % 
P1: A/A; B/b 
P2: A/A; B/B 
50 % 12.5 % 
P1: A/A; B/B 
P2: A/A; B/B 
100 % 25 % 
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Parents’ (P1 and P2) haplotypes for the two candidate loci A and B are written in 
capital letters for the desired haplotype and in lowercase for the WT haplotype. 
Probabilities are calculated according to Mendelian rules. 
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V. DISCUSSION 
Although many important insights into pathological mechanisms have been 
gained during the last decades and novel forms of therapy have been developed, 
Cystic Fibrosis still remains a disease that severely reduces the life expectancy of 
affected patients and thus warrants all the scientific efforts concerning this field 
(Spielberg and Clancy 2016). Animal models are a unique and essential tool for a 
better understanding of CF and the testing of new therapeutic approaches. Out of 
all established animal models for CF, the porcine model shows the closest 
resemblance to the classic human CF phenotype and thus enables a simplified 
translation of findings to humans. Studies on neonatal tracheal tissue from CF KO 
and WT piglets generated by breeding have given important new insights into 
mucus composition and mucociliary transport in the airways (see Figure 26 and 
Figure 27) and many collaboration partners are interested in tissue from newborn 
piglets. However, since not all experiments can be performed on neonatal piglets, 
the availability of older, living CF pigs is required. For this purpose, the main 
limitation of the utility of the porcine CF model has to be overcome - the lethal 
neonatal intestinal obstruction by meconium. In this thesis, two different 
approaches to rescue the severe intestinal phenotype were evaluated; one 
approach was the selective transgenic expression of CFTR in the intestine, while 
the second approach investigated the contribution of modifier genes to an 
improved intestinal phenotype in CF KO piglets. In addition, I characterized the 
porcine CF model with different molecular biological methods. 
 
The detection of CFTR in the intestine is only successful using one particular 
antibody under very specific conditions 
 
The investigation of CFTR at protein level proved to be very difficult and it 
turned out that the detection was only successful in the intestine using one 
particular antibody, Ab 596, under very specific conditions. Ten commercially 
available primary antibodies that were described to detect porcine CFTR were 
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evaluated for their specificity and sensitivity in paraffin-embedded and frozen 
sections. In general, the advantages of frozen sections are that the antigenicity is 
often better preserved, whereas the tissue and cellular morphology are better and 
the handling and storage are easier when paraffin-embedded slides are used 
(Fischer, Jacobson et al. 2008, Wild 2013). 
In paraffin-embedded tissue, none of the examined antibodies recognized the 
correct CFTR protein, even though different antigen retrieval techniques both for 
heat-induced and proteolytic-induced epitope retrieval were tested. Although the 
antibodies detected the typical expression pattern of CFTR in WT intestine with 
the strongest signal intensity in the epithelial crypts and a decrease along the 
crypt-villus axis, the main problem was that the staining pattern was identical with 
that of CF KO intestine (see Figure 16). Interestingly, this feature could also be 
detected in western blots, where several antibodies recognized a band of the 
correct size both in WT and CF KO tissue (see Figure 17 (A)). A potential 
explanation for this finding could be the fact that in this thesis the specificity of 
antibodies was evaluated using porcine KO tissue as a “gold standard” negative 
control and not only by staining with the secondary antibody; an experiment that 
has not been done like this before, as no “real” negative control had been available 
until previously. As CFTR is a member of the ABC transporters that are 
characterized by highly-conserved motifs in the nucleotide-binding domains 
(Rees, Johnson et al. 2009), antibodies against CFTR might also recognize 
epitopes on other membrane transport proteins with a distribution pattern similar 
to CFTR. This idea is fortified by a study in which antibodies against different 
regions of CFTR recognized not only CFTR, but also immunologically related 
proteins with a comparable molecular mass and distribution pattern (Walker, 
Watson et al. 1995). 
For the detection of human CFTR in frozen sections with the antibodies from the 
CF folding consortium, a detailed protocol was available (Kreda and Gentzsch 
2011). As the amino acid sequences from all purchased antibodies showed a 
100 % identity between human and pig, it was expected that this protocol should 
also work for the specific detection of CFTR in porcine tissue. However, neither 
in frozen sections nor in methacarn sections with expected antigenicity 
comparable to frozen sections (Mitchell, Ibrahim et al. 1985), a specific staining 
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of CFTR was detected with this protocol. This indicates that antigen-antibody 
interactions differ between species in spite of identical epitope sequences. 
Only with one very specialized protocol the specific detection of CFTR worked 
reliably on cryo-sections from the intestine of WT animals, while CF KO tissue 
was negative. In the WT lung, only a very weak staining of the submucosal glands 
was detected. This finding can be easily explained by the fact that CFTR 
antibodies are often not sensitive enough to detect endogenous levels of the 
protein that is expressed only in very low abundance in many tissues (Doucet, 
Mendes et al. 2003). The expression analysis of CFTR at mRNA level showed 
that CFTR expression in the proximal jejunum is about ten times higher than in 
the lung (see Figure 24). There might be two possible issues contributing to the 
specific detection of CFTR with this protocol. The freezing method with pre-
incubation in 2 % PFA and 30 % sucrose before snap-freezing embedded in OCT 
compound in an ethanol/dry ice bath should only lead to a better conservation of 
tissue morphology, but not interfere with the antigenicity of epitopes, which is in 
general better preserved in frozen than in paraffin-embedded tissue (Wild 2013, 
Hare, George et al. 2014). The second main difference to all other examined 
protocols was the treatment of sections with Triton X-100. Triton X-100 is known 
to increase the permeability of tissue for antibodies by destroying the membrane 
structure (Chen, Cho et al. 2010) and might thereby lead to a better detection of 
CFTR with Ab 596 that recognizes a part of the intracytoplasmatic NBD2 that 
could otherwise be difficult to access. One problem with studies on the 
distribution pattern of CFTR is, that even when only experiments on porcine 
tissue are taken into account, the results are inconsistent. Plog, Mundhenk et al. 
(2010) describe that porcine CFTR is expressed in ciliated epithelial cells and 
goblet cells in the nasal, tracheal, and bronchial mucosa but not in the alveolar or 
bronchiolar epithelia or submucosal glands. In contrast, Ballard, Trout et al. 
(1999) localized CFTR mainly to the ducts of submucosal glands and in weaker 
intensity to cells of the bronchial surface epithelium, an expression pattern 
corresponding to the weak staining of submucosal glands we detected in WT lung 
tissue (see Figure 14 (B)). Therefore, it is strongly recommended to repeat the 
working protocol with other antibodies in order to evaluate if these antibodies can 
be utilized for the specific detection of CFTR and if they recognize the same 
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distribution pattern as Ab 596. Only when a panel of antibodies recognizing 
different regions of CFTR detects the identical distribution pattern, a reliable 
conclusion on the expression of CFTR in porcine tissue can be reached. As the 
primary aim was to find an antibody that specifically detected CFTR in paraffin-
embedded tissue, a panel of monoclonal antibodies recognizing specific peptide 
sequences of porcine CFTR were generated by immunization of rats and mice via 
the hybridoma technique by the AG Kremmer, Institute of Molecular 
Immunology Helmholtz Center Munich (Rottach, Kremmer et al. 2008). These 
antibodies are currently evaluated using WT and CF KO tissue and will be 
analyzed in more detail both for their utility for western blot and 
immunohistochemistry in the future. 
 
Not only the intensity, but also the localization of CFTR expression affects the 
severity of meconium ileus in gut-modified CFTR-/- piglets 
 
The correlation of CFTR expression levels with the intestinal phenotype in gut-
modified CFTR-/- piglets revealed that the improvement of the MI was more 
pronounced when CFTR expression levels were higher in the distal parts of the 
intestine. In contrast, when high CFTR expression levels were restricted to the 
proximal parts of the small intestine, the intestinal phenotype did not differ from 
normal CF KO piglets. In the ileum of founder #2477 with the clearest 
improvement of MI, almost the same levels of CFTR were detected as in the WT 
ileum, albeit without an increased survival rate (see Figure 24). This finding 
remains contrary to a CF mouse model, in which only 5 % of normal CFTR 
expression levels assured the survival from intestinal disease (Dorin, Farley et al. 
1996). However, a direct translation of findings in CF mice to the porcine CF 
model is difficult due to differences in the pathological mechanisms involved in 
the obstructive intestinal disease in these two species. Another study performed by 
Stoltz, Rokhlina et al. (2013) in CF KO piglets states that 20 % of WT CFTR 
mRNA expression in the ileum of gut-corrected CFTR-/- piglets is sufficient to 
rescue the lethal intestinal phenotype. This contradiction might be explained by 
the fact that in this model CFTR expression was only measured in one part of the 
intestine, the ileum, and not in five different regions of the intestine as in our 
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study. Therefore, it is unclear, whether higher levels of CFTR were detected in 
these piglets in other parts of the intestine that were the underlying reason for the 
increased survival and whether the expression levels in the ileum do have a value 
in predicting the severity of the intestinal phenotype. 
We claim that in our examined gut-modified CFTR-/- piglets the survival was not 
rescued, in spite of high CFTR expression levels in proximal parts of the intestine, 
due to the lack of CFTR expression in the colon. We hypothesize that the 
localization of transgenic CFTR expression in the colon is as important as the 
intensity of the expression levels. There are several potential reasons why the 
prevalence of MI in CF piglets is so much higher than in other animal models for 
CF (ferret 75 %; mice develop DIOS-like obstruction around weaning) or affected 
humans (up to 20 %) (Borowitz and Gelfond 2013). Studies performed by Plog, 
Mundhenk et al. (2010) justify the 100 % incidence of MI in pigs with the strong 
expression of CFTR in the ileum and colon of WT piglets. Apart from the missing 
CFTR expression in the ileum and colon, other features are known to affect the 
severity and incidence of MI. The existence of alternative chloride currents in the 
intestine contributes to a modulation of gastrointestinal disease severity in CF 
mice and might be a reason for the less pronounced intestinal phenotype in CF 
mice models in comparison to the porcine model (Rozmahe, Wilschanski et al. 
1996). CF patients carrying severe mutations in the CFTR gene are at a higher risk 
to develop MI (Dupuis, Keenan et al. 2015), so the fact that CF pigs and ferrets 
carry a null mutation should explain the high incidence of MI in these models. 
Other findings contributing to the high incidence of MI are the specific anatomy 
of the porcine large intestine, physiological differences in the secretory 
mechanisms in the large intestine in relation to other species or the narrow inbred-
status of the experimental CF herd (Rogers, Stoltz et al. 2008, Sun, Sui et al. 
2010). 
Another indication that missing CFTR expression in the colon is primarily 
responsible for the severe intestinal disease in CF pigs is the atretic microcolon 
found in CF KO piglets (Meyerholz, Stoltz et al. 2010, Klymiuk, Mundhenk et al. 
2012) that seems to be the main obstacle to the removal of meconium. Whether 
the atresia of the colon is really caused primarily by a developmental effect due to 
the lack of CFTR or develops subsequently because the functional obstruction 
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leads to a missing distension by luminal contents (Amodio, Berdon et al. 2012), 
should be analyzed in greater detail. However, the fact that from the first trimester 
onwards CFTR is expressed throughout the intestine in high levels during fetal 
development, gives a strong hint to the important role of CFTR in organ 
development (Tizzano, Chitayat et al. 1993). Only recently, Than, Linnekamp et 
al. (2016) demonstrated the importance of CFTR in the regulation of large 
intestinal stem cells since CFTR acts as a tumor suppressor gene for colorectal 
cancer in mice and humans. This implicates that CFTR expression in the distal 
parts of the intestine is a major contributor to the correct formation and 
development of the intestine. 
An important question in this context is why the expression of CFTR is so high in 
the colon of pigs. This might be due to an adaptive process to the normal 
physiology of digestion in the porcine large intestine. CFTR-expressing goblet 
cells in the intestine form the characteristic two-layer mucus that serves as part of 
the innate immune system in form of a mucosal barrier (Kreda, Davis et al. 2012). 
In the porcine large intestine, dietary fibers are fermented to short chain fatty-
acids (Jha and Berrocoso 2016) that stimulate colonic mucin production (Barcelo, 
Claustre et al. 2000) and gut microbiota might even utilize released mucins as 
energy source (Stanley, Ram et al. 1986). The magnified stimulation of mucus 
production and digestion by gut microbiota might therefore have led to an 
adaptive increase of goblet cell numbers in the large intestine. 
 
The expression pattern of porcine FABP2 limits the utility of the promoter to 
drive a selective expression of CFTR in the intestine 
 
In order to achieve a selective expression of CFTR in the intestine of gut-modified 
CFTR-/- piglets, the promoter of the porcine FABP2 gene was employed. The 
FABP2 protein is involved in the uptake and cellular transport of dietary long 
fatty-acids and therefore it is expressed predominantly and in high abundance in 
the intestine (Jiang and Li 2006). As the mRNA of FABP2 is the most abundant 
RNA sequence in the intestine (Bass 1988) and the cytosolic FABPs represent up 
to 2 % of cytosolic proteins in the enterocytes (Ockner and Manning 1974), the 
expression levels of the transgenic construct were expected to be high. In contrast 
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to other studies that employed the FABP2 promoter from the rat for the transgenic 
expression of CFTR in the mouse (Zhou, Dey et al. 1994) and pig (Stoltz, 
Rokhlina et al. 2013), we decided to use a homologous promoter because its 
activity should be stronger and the distribution pattern more precise in the same 
species (Rathore and Sunilkumar 2005). In 33 % of all examined gut-modified 
CFTR-/- founder animals, however, CFTR expression was not limited to the 
intestine but could be detected, albeit with lower abundance, in other CF-relevant 
organ systems such as the airways or the pancreas (see Figure 23). Therefore, the 
utility of these animals would be limited as they would most likely not develop 
the characteristic CF phenotype. This finding remains contrary to the US 
transgenic porcine CF model that utilized the rat FABP2 promoter for the 
selective expression of CFTR in the intestine and did not exhibit any extra-
intestinal expression (Stoltz, Rokhlina et al. 2013). However, consistent with our 
results, in a CF mouse model expressing human CFTR under the control of the rat 
FABP2 promoter, several lines showed an extra-intestinal expression (Zhou, Dey 
et al. 1994), indicating that both rat and porcine FABP2 expression might not be 
limited to the intestine. Measuring the expression levels of FABP2 by quantitative 
PCR and sequencing of amplification products revealed that very high levels are 
consistently found in all parts of the small intestine, with highest levels in the 
jejunum, but also that small levels are detected in all other examined organs (see 
Figure 22 and Figure 25). Other studies confirm that both rat and porcine FABP2 
transcripts are detected in lower levels in organs other than the intestine (Gordon, 
Elshourbagy et al. 1985, Jiang and Li 2006). Whether the detected CFTR 
expression in extra-intestinal organs in our gut-modified CFTR-/-piglets was 
triggered by the low amount of FABP2 expression in other organs or was caused 
by the specific integration side of the transgenic vector, could only be clarified by 
a whole genome sequencing of these piglets. However, expression patterns and 
the corresponding results in the transgenic mouse model (Zhou, Dey et al. 1994) 
provide a strong indication that the FABP2 promoter is not suitable to drive an 
intestine-selective CFTR expression.  
Another aspect concerning the utility of the FABP2 as promoter for the expression 
of CFTR is the stage-specific expression during fetal development. As we 
conclude that CFTR expression is essential for the development of the intestine 
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and CFTR expression can be detected as early as in the first trimester of 
pregnancy in humans (Tizzano, Chitayat et al. 1993), a similar developmental 
expression of FABP2 might be important to prevent the formation of a 
microcolon. A closer look at developmental expression patterns of rat and mouse 
FABP2 showed that this gene is only expressed during the late trimester of 
pregnancy in very low levels with a four-fold increase of expression levels within 
the first 24 h after birth by gene induction (Gordon, Elshourbagy et al. 1985, 
Green, Cohn et al. 1992). In contrast, studies on fetal human tissue report a 
FABP2 expression very early in the gestational period (Levy, Menard et al. 2009). 
As no studies on the developmental expression pattern of porcine FABP2 exist, 
the suitability of the promoter to drive CFTR expression during early fetal 
development remains a feature that should be further investigated. 
The last aspect that should be considered in the evaluation of the usefulness of the 
FABP2 promoter is that expression analysis of gut-modified CFTR-/- piglets 
indicates the necessity of CFTR expression in the large intestine to ensure survival 
(see Figure 24). Therefore, an ideal promoter should be characterized by high 
expression in the distal parts of the intestine. FABP2 expression analysis at 
mRNA level showed that FABP2 is predominantly expressed in the small 
intestine and no measurable amounts are detected in the colon (see Figure 22). 
Corresponding to this finding, FABP2 protein contents in the human small 
intestine are significantly higher than in the colon, with highest levels in the 
jejunum (Pelsers, Namiot et al. 2003). The absence of FABP2 expression in the 
colon may have been the underlying reason for the severity of MI that could not 
be improved to a sufficient degree in our gut-modified CFTR-/- piglets. 
 
The genetic background of CFTR-/- piglets influences the severity of 
meconium ileus 
 
The finding with the strongest impact on future research concerning the porcine 
CF model was that the severity of meconium ileus shows variability among CF 
KO piglets produced by conventional breeding (see Figure 28). Until now all 
groups working with CF pigs have reported a 100 % penetrance of MI, 
independent from the mutation in the CFTR gene (Rogers, Stoltz et al. 2008, 
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Ostedgaard, Meyerholz et al. 2011, Klymiuk, Mundhenk et al. 2012). In contrast, 
in other species a high variability of the severity of the intestinal phenotype is 
reported in CF, which is mainly influenced by the genetic background. MI in 
human CF patients is one of several CF manifestations, such as CFRD (Blackman, 
Commander et al. 2013) or susceptibility to chronic infections with P. aeruginosa 
(Emond, Louie et al. 2012), which show very high heritability values. This 
indicates the strong contribution of genetic factors apart from the CFTR mutation 
to the phenotypic variety (Brennan and Schrijver 2016). Already in 1996, in CF 
mice models the existence of secondary genetic factors influencing the intestinal 
phenotype was described (Rozmahe, Wilschanski et al. 1996). Since, a range of 
potential candidate genes like members of the solute carrier protein family or 
multiple apical plasma membrane constituents have been identified by genome-
wide association studies (Sun, Rommens et al. 2012). However, in this study we 
could demonstrate for the first time the presence of porcine modifier genes 
contributing to a variable severity of MI in the CF pig model (see Figure 30). 
Only in rare cases modifier genes associated with intestinal obstruction were 
shown to have the same effect in two different species, like CLCA1 (Van der 
Doef, Slieker et al. 2010) or MSRA (Henderson, Doshi et al. 2012) in CF mice 
and humans. Nevertheless, it is important to compare the two candidate loci on 
chromosome 10 and 16 in the porcine genome to regions in the human genome 
syntenic to these loci. Thereby we can examine whether genes reported to modify 
the CF phenotype in humans lay within this region and might therefore also be 
potential modifier genes for the porcine model. However, first analyses indicate 
that no described human modifier gene is expressed in the region of interest. Next 
steps will include a more detailed examination of the two porcine candidate loci in 
order to determine whether genes with a potential functional correlation with the 
intestinal obstruction are expressed in this region. The majority of human modifier 
genes for MI encode proteins that might interact directly with the functional 
defects leading to the CF phenotype, e.g. by regulation of transepithelial 
electrolyte and bicarbonate transport (Dorfman, Li et al. 2009) or modulation of 
proteolysis of the abnormal proteinaceous meconium (Henderson, Doshi et al. 
2012). In future studies it has to be clarified, whether SNPs lie within the coding 
region of a gene, directly interfering with protein function, or are located at 
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regulatory regions, affecting the binding of transcription factors and thereby 
increasing or suppressing gene expression (Bush 2006). 
In parallel to a detailed analysis of the two candidate loci it will be essential to 
produce new CF piglets with an improved intestinal phenotype in order to 
investigate if these piglets can completely remove meconium and survive the first 
critical days of life. These piglets can be generated by two different ways – either 
by reclonation of one of the improved CF piglets via SCNT and ET or by 
conventional breeding after a screening of the breeding herd for the desired 
haplotypes. The generation of “gut-improved” CF piglets by SCNT and ET is a 
fast and efficient method to produce a small number of animals with the desired 
genotype and is therefore suited for the evaluation of the intestinal phenotype as a 
kind of “proof of concept” study. However, it has to be taken into account that in 
the recloned piglets from gut-modified CF founder #2478, the improved intestinal 
phenotype was not reproducible (see Figure 7) and that recloned “gut-improved” 
piglets might therefore not exhibit the same level of improvement as the donor 
animals. In addition, the production of large numbers of viable animals via this 
method is not feasible due to low cloning efficiency (see Table 14 and Table 15) 
and a high rate of phenotypical abnormalities (see Figure 7), which might be due 
to epigenetic reprogramming or genomic damage of the donor cells (Cho, Kim et 
al. 2007). Therefore, all effort will be made to produce these gut-improved CF 
piglets by conventional breeding in the future. By screening of the breeding herd 
for the two candidate loci we will be able to selectively mate animals with a 
specific haplotype to increase the probability of CF KO piglets homozygous for 
both loci according to Table 20. If “gut-improved” CF KO piglets can survive the 
first critical days, they will make an ideal animal model for Cystic Fibrosis. In 
contrast to the porcine CF model with transgenic expression of CFTR in the 
intestine, the severity of meconium ileus is rescued in these piglets by naturally 
occurring modifier genes, whose existence is also described in human CF patients. 
Therefore, a living “gut-improved” CF pig will be an ideal large animal model for 
the investigation of unknown pathological mechanisms and testing of novel forms 
of therapy. It opens new prospects for CF research and can thereby lead to a better 
understanding of Cystic Fibrosis or even the development and evaluation of 
potential curative treatments. 
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VI. SUMMARY 
The pig as an animal model for Cystic Fibrosis – approaches to overcome the 
lethal intestinal phenotype 
Cystic Fibrosis (CF) is one of the most common lethal autosomal recessive 
hereditary diseases in people from Caucasian origin. Mutations in the gene 
encoding the anion channel Cystic Fibrosis Transmembrane Conductance 
Regulator (CFTR) cause defective transepithelial electrolyte transport. The 
consequence of this pathophysiological mechanism is a multisystemic disease 
mainly affecting the airways, the gastrointestinal tract and the pancreas. Chronic 
inflammations and infections of the respiratory tract are the main reasons for the 
decreased survival rate of CF patients. Although novel drugs, so-called 
“modulators”, targeting specific mutation classes directly at the genetic or protein 
level have been developed in recent years, treatment options are still primarily 
limited to symptomatic therapy. So far, five different established animal models 
are available for CF research. As the porcine CF model bears the strongest 
resemblance to the classic human CF phenotype, important insights into the 
underlying pathological mechanisms involved in the development of airway 
disease have been gained by studying this model organism. The main aspect 
limiting the suitability of the porcine CF model is the lethal neonatal meconium 
ileus (MI) that occurs with a penetrance of 100 % and proves to be fatal if not 
surgically corrected. 
In this thesis, I evaluated two different approaches to rescue the lethal intestinal 
phenotype of CF piglets. The first approach focused on the idea that the transgenic 
expression of CFTR under the control of the intestine-specific fatty-acid binding 
protein (FABP2) promoter should ameliorate the intestinal obstruction in CF 
piglets without interfering with other typical organ manifestations of CF. Despite 
an elaborate supporting treatment, none of the transgenic gut-modified piglets was 
able to remove the meconium completely. The examination of the intestinal 
phenotype consistently revealed an improvement of MI, indicated by a more distal 
localization and the absence of diverticulosis. The establishment of a fast 
genotyping protocol in less than three hours and the sequencing of amplified DNA 
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confirmed the genetic CF background and the integration of the transgenic vector 
into the CF genome. By quantitative PCR, I determined the expression level of 
CFTR in different parts of the intestine and other CF-relevant organs and could 
demonstrate that 33 % of all animals expressed CFTR in all organs. In all other 
tested animals, the expression of CFTR was restricted to the small intestine and 
correlated positively with the expression of FABP2. A correlation of the intestinal 
phenotype with CFTR expression levels revealed that the higher the expression 
levels were in the distal parts of the intestine, the more distinct was the 
improvement in the phenotype. In addition, I confirmed the absence of CFTR in 
the intestine and lungs of CF piglets by immunohistochemistry and 
immunofluorescence. 
In the second part of the thesis, I investigated whether modifier genes contributed 
to the varying severity of meconium ileus that naturally occurred when CF pigs 
were produced by conventional breeding. In a hypothesis-driven “candidate gene” 
approach, I demonstrated by sequencing that the integrity of CLCA4b does not 
affect the intestinal phenotype in CF piglets. The genome-wide search for single 
nucleotide polymorphisms (SNPs) in CF piglets with an improved phenotype in 
comparison to other CF piglets revealed two potential candidate loci on 
chromosome 10 and 16, which have to be combined in an autosomal recessive 
way to improve the intestinal phenotype. 
In conclusion, I could demonstrate two different ways to improve the lethal 
intestinal phenotype in a porcine model for Cystic Fibrosis in this thesis. The 
intestinal phenotype of transgenic gut-modified CF piglets was clearly alleviated, 
however, not to a sufficient degree to ensure survival. Presumably, this was 
caused by the absence of CFTR expression in the colon. In addition, the FABP2 
promoter was not suitable to drive an intestine-specific CFTR expression with 
high levels in the distal parts. In contrast, the second approach looks very 
promising. The discovery of potential modifier genes that contribute to a variable 
intestinal phenotype in CF piglets harbors great potential for the development of a 
living porcine CF model. 
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VII. ZUSAMMENFASSUNG 
Das Schwein als Tiermodell für Mukoviszidose - Ansätze zur Behebung des 
tödlichen intestinalen Phänotyps 
Mukoviszidose, auch zystische Fibrose (CF) genannt, gehört zu einer der 
häufigsten tödlichen autosomal rezessiven Erbkrankheiten bei Menschen mit 
kaukasischem Hintergrund. Mutationen des CFTR-Gens, das für den Anionen-
kanal Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) codiert, 
verursachen einen fehlerhaften Elektrolyttransport an der Epitheloberfläche. Die 
Folge ist eine multisystemische Erkrankung, die vor allem die Luftwege, den 
Darmtrakt und die Bauchspeicheldrüse betrifft. Chronische Entzündungen und 
Infektionen des Atemtrakts sind die Hauptursachen für die eingeschränkte 
Lebenserwartung von CF-Patienten. Obwohl in den letzten Jahren neue 
Medikamente, sogenannte Modulatoren, entwickelt wurden, die gezielt auf 
Genom- oder Proteinebene spezielle Mutationsklassen angreifen, beschränkt sich 
die Behandlung auch heutzutage vorrangig auf eine symptomatische Therapie. 
Fünf verschiedene etablierte Tiermodelle stehen bislang der CF-Forschung zur 
Verfügung. Da das Schweinemodell dem klassischen Phänotyp beim Menschen 
am stärksten ähnelt, konnten anhand dieses Tiermodells wichtige Erkenntnisse 
über die pathophysiologischen Prozesse, die der Entwicklung der Erkrankung der 
Atemwege zugrunde liegen, gewonnen werden. Der Nutzen des CF-
Schweinemodells ist jedoch enorm eingeschränkt, da es bei neugeborenen CF-
Ferkeln mit einer Inzidenz von 100 % zu einem Mekoniumileus (MI) kommt, der 
ohne Operation tödlich verläuft. 
In meiner Dissertation entwickelte ich zwei verschiedene Ansätze, um den 
tödlichen Phänotyp im Darm von neugeborenen CF-Ferkeln zu beheben. Der erste 
Ansatz basierte auf der Hypothese, dass eine transgene Expression von CFTR 
unter der Kontrolle des Promoters des nur im Darm exprimierten Gens FABP2 
(fatty-acid binding protein) zu einer Verbesserung des MI führen sollte, ohne 
dabei andere CF-relevante Organe zu beeinflussen.  
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Trotz einer ausgeprägten unterstützenden Behandlung konnte keines der 
transgenen „darmverbesserten“ Ferkel das Mekonium vollständig ausscheiden. 
Die visuelle Begutachtung des Darmtrakts zeigte bei allen Tieren eine 
Verbesserung des MI mit einer distaleren Lokalisation und einem Fehlen der 
Divertikulose. Die Genotypisierung und Sequenzierung der amplifizierten DNA 
bestätigte die Genetik der CF-Ferkel und die Integration des transgenen Vektors 
in das Genom. Mit quantitativer PCR wurde die Menge an exprimiertem CFTR in 
verschiedenen Darmabschnitten und anderen CF-relevanten Organen bestimmt. 
Dabei exprimierten 33 % der untersuchten Tiere CFTR in allen Organen. Bei allen 
anderen getesteten Tieren war die Expression ausschließlich auf den Dünndarm 
beschränkt und korrelierte positiv mit dem Expressionsmuster von FABP2. Die 
Korrelation zwischen dem Darmphänotyp und der Menge an exprimiertem CFTR 
zeigte, dass die Verbesserung des Darmphänotyps umso ausgeprägter war, je 
höher die Expression in distaleren Darmabschnitten war. Zusätzlich konnte ich 
mit immunhistochemischen und Immunfluoreszenz-Methoden bestätigen, dass im 
Darm und in der Lunge von CF Ferkeln kein CFTR Protein exprimiert wird. 
Im zweiten Teil der Dissertation wurde untersucht, ob Modifier-Gene für die 
unterschiedliche Ausprägung des Darmphänotyps, die natürlicherweise bei 
gezüchteten CF Ferkeln auftrat, verantwortlich sind. In einem hypothesen-
gesteuerten Kandidatengen-Ansatz wurde gezeigt, dass Deletionen im CLCA4b-
Gen in keinem Zusammenhang mit dem verbesserten Darmphänotyp stehen. Die 
genomweite Suche nach Einzelnukleotidpolymorphismen, in denen sich CF-
Ferkel mit verbessertem Phänotyp von anderen CF-Ferkeln unterscheiden, ergab 
zwei potentielle Kandidatenregionen auf den Chromosomen 10 und 16, die 
autosomal rezessiv miteinander kombiniert sein müssen. 
Zusammengefasst beschreibt diese Dissertation zwei verschiedene Ansätze, den 
tödlichen intestinalen Phänotyp in einem Schweinemodell für Mukoviszidose zu 
beheben. Die Ausprägung des Darmphänotyps in dem transgenen CF-
Schweinemodell konnte zwar deutlich verbessert werden, jedoch nicht in einem 
solchen Maß, dass das Überleben der Tiere gewährleistet wurde. Die Ursache 
dafür liegt vermutlich in der fehlenden Expression von CFTR im Colon. Des 
Weiteren ist der FABP2 Promoter ungeeignet, eine darmspezifische CFTR-
Expression mit hohen Spiegeln im Dickdarm zu bewirken.   
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Im Gegensatz dazu ist der zweite Ansatz durchaus vielversprechend. Die 
Entdeckung von möglichen Modifier-Genen, die den Darmphänotyp von CF-
Ferkeln beeinflussen, birgt großes Potential für die Entwicklung eines lebenden 
CF-Schweinemodells. 
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